15TH INTERNATIONAL MYELOMA WORKSHOP

SEPTEMBER 23–26, 2015
Rome, Auditorium Parco della Musica

PROGRAM
Dear Colleagues and Friends,

It is my great pleasure and honor to invite you to attend the 15th International Myeloma Workshop to be held in Rome, Italy, from September 23rd to 26th, 2015. During this important biannual event, the emerging advances in the biology and treatment of multiple myeloma, as well as debates on more controversial arguments, and consensus report will be presented. The location of the Workshop, in the Auditorium Parco della Musica which is right in the city centre, will ensure that you all enjoy both the meeting and the fascinating city of Rome.

I am very much looking forward to welcoming you to Rome in September 2015!

Antonio Palumbo
President, 15th International Myeloma Workshop
<table>
<thead>
<tr>
<th>Wednesday, September 23, 2015</th>
<th>Thursday, September 24, 2015</th>
<th>Friday, September 25, 2015</th>
<th>Saturday, September 26, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>07.00-08.00</td>
<td>07.00-08.00</td>
<td>07.00-08.00</td>
<td>07.00-08.00</td>
</tr>
<tr>
<td>MEET THE EXPERTS</td>
<td>MEET THE EXPERTS</td>
<td>MEET THE EXPERTS</td>
<td>MEET THE EXPERTS</td>
</tr>
<tr>
<td>08.00-09.00</td>
<td></td>
<td>08.00-10.20</td>
<td>08.00-09.00</td>
</tr>
<tr>
<td>09.30-09.45 OPENING CEREMONY</td>
<td>08.00-10.20 NEWLY DIAGNOSED MULTIPLE MYELOMA YOUNG PATIENTS</td>
<td>09.00-10.00 NEWLY DIAGNOSED MULTIPLE MYELOMA ELDERLY PATIENTS</td>
<td>09.00-10.00 RISING STARS AWARD</td>
</tr>
<tr>
<td>10.00-11.00 TIMELAPSE</td>
<td>10.00-11.00 How to introduce Technology Assessment in Clinical Studies</td>
<td>10.00-10.15 BART BARLOGIE YOUNG INVESTIGATOR AWARD</td>
<td>10.00-10.15 BART BARLOGIE YOUNG INVESTIGATOR AWARD</td>
</tr>
<tr>
<td>10.45-10.50 ROBERT KYLE LECTURE</td>
<td>10.20-10.50 Coffee Break</td>
<td>10.50-12.20 PRIME ONCOLOGY SPONSORED SYMPOSIUM supported by TAKEDA ONCOLOGY Building on the Foundation of Proteasome Inhibition in Multiple Myeloma</td>
<td>10.30-11.00 DEBATE</td>
</tr>
<tr>
<td>11.00-12.00 GENOMICS AND MICROENVIRONMENT</td>
<td>10.50-12.20 PRIME ONCOLOGY SPONSORED SYMPOSIUM supported by TAKEDA ONCOLOGY Building on the Foundation of Proteasome Inhibition in Multiple Myeloma</td>
<td>10.50-12.20 CELGENE CORPORATION SPONSORED SYMPOSIUM The Role of Immunomodulators in the Future Landscape of Multiple Myeloma</td>
<td>10.30-11.00 DEBATE</td>
</tr>
<tr>
<td>12.00-13.00 Lunch</td>
<td>12.00-13.00 Lunch</td>
<td>12.00-13.00 Lunch</td>
<td>12.30-13.00 CLOSING CEREMONY</td>
</tr>
<tr>
<td>13.00-14.00 Lunch</td>
<td>13.00-14.00 Lunch</td>
<td>13.00-14.00 Lunch</td>
<td>13.00-14.00 Lunch</td>
</tr>
<tr>
<td>14.00-15.00 DIAGNOSTIC AND RESPONSE CRITERIA</td>
<td>13.20-14.50 AMGEN SPONSORED SYMPOSIUM Delving Into the Deep – Advances in the Treatment of Multiple Myeloma in 2015</td>
<td>13.20-14.50 JANSSEN SPONSORED SYMPOSIUM The Clinical Rationale and Experience with Monoclonal Antibodies in Multiple Myeloma</td>
<td>13.00-14.00 Lunch</td>
</tr>
<tr>
<td>15.00-16.00 RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS</td>
<td>14.50-16.30 RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS</td>
<td>14.50-16.30 IMMUNOTHERAPY</td>
<td>16.00-17.00 Coffee Break</td>
</tr>
<tr>
<td>16.00-17.00 Coffee Break</td>
<td>16.00-17.00 Coffee Break</td>
<td>16.00-17.00 Coffee Break</td>
<td>16.00-17.00 Coffee Break</td>
</tr>
<tr>
<td>16.30-18.00 NOVARTIS ONCOLOGY SPONSORED SYMPOSIUM Understanding the Role of Epigenetics in the Pathogenesis and Treatment of Multiple Myeloma</td>
<td>17.00-18.40 ALLOGENEIC TRANSPLANTATION AND NOVEL AGENTS</td>
<td>17.00-18.40 SPECIAL CONDITIONS</td>
<td>17.00-18.40 SPECIAL CONDITIONS</td>
</tr>
<tr>
<td>17.00-18.00 Waldenstrom's Award</td>
<td>17.00-18.40 ALLOGENEIC TRANSPLANTATION AND NOVEL AGENTS</td>
<td>17.00-18.40 SPECIAL CONDITIONS</td>
<td>17.00-18.40 SPECIAL CONDITIONS</td>
</tr>
<tr>
<td>18.00-19.00 Patient Association Talks</td>
<td>18.00-18.45 Waldenstrom's Award</td>
<td>18.40-19.40 POSTER SESSION I</td>
<td>18.40-19.40 POSTER SESSION II</td>
</tr>
<tr>
<td>20.00-21.00 Welcome Reception</td>
<td>19.30-21.30 Welcome Reception</td>
<td>20.00-21.00 Welcome Reception</td>
<td>21.00-22.30 Welcome Reception</td>
</tr>
<tr>
<td>Faculty Name</td>
<td>Institution</td>
<td>City, Country</td>
<td></td>
</tr>
<tr>
<td>----------------------</td>
<td>------------------------------</td>
<td>--------------------</td>
<td></td>
</tr>
<tr>
<td>Kenneth C. Anderson</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michel Attal</td>
<td>Toulouse, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Daniel Auclair</td>
<td>Norwalk, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hervé Avet-Loiseau</td>
<td>Toulouse, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>David E. Avigan</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nizar J. Bahlis</td>
<td>Calgary, Canada</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Luca Baldini</td>
<td>Milano, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bart Barlogie</td>
<td>New York, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Leif P. Bergsagel</td>
<td>Scottsdale, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Joan Bladé</td>
<td>Barcelona, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mario Boccadore</td>
<td>Torino, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lawrence Boise</td>
<td>Atlanta, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sara Bringhen</td>
<td>Torino, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jamie Cavenagh</td>
<td>London, UK</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Michele Cavo</td>
<td>Bologna, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raymond L. Comenzo</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alessandro Corso</td>
<td>Pavia, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Carlo Croce</td>
<td>Columbus, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Faith Davies</td>
<td>Little Rock, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francesco Di Raimondo</td>
<td>Catania, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angela Dispenzier</td>
<td>Rochester, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Brian Durie</td>
<td>Los Angeles, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hermann Einsele</td>
<td>Würzburg, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Monika Engelhardt</td>
<td>Freiburg, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thierry Facon</td>
<td>Lille, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jean-Paul Fermand</td>
<td>Paris, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rafael Fonseca</td>
<td>Scottsdale, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francesca Gay</td>
<td>Torino, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Morie A. Gertz</td>
<td>Rochester, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Irene M. Ghobrial</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sergio A. Giralt</td>
<td>New York, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hartmut Goldschmidt</td>
<td>Heidelberg, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Roman Hájek</td>
<td>Ostrava, Czech Republic</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jean-Luc Harousseau</td>
<td>Saint Denis La Plaine, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jian Hou</td>
<td>Shanghai, China</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cynthia Iglesias</td>
<td>York, United Kingdom</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tadao Ishida</td>
<td>Sapporo, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sudar Jagannath</td>
<td>New York, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrzej Jakubowiak</td>
<td>Chicago, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nicolaus Kroeger</td>
<td>Hamburg, Germany</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Shahj K. Kumar</td>
<td>Rochester, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Kyle</td>
<td>Rochester, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>C. Ola Landgren</td>
<td>New York, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Alessandra Larocca</td>
<td>Torino, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xavier Leleu</td>
<td>Lille, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sagar Loniol</td>
<td>Atlantic, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heinz Ludwig</td>
<td>Vienna, Austria</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Angelo Maiolino</td>
<td>Rio de Janeiro, Brazil</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fabio Malavasi</td>
<td>Torino, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Thomas G. Martin</td>
<td>San Francisco, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria-Victoria Mateos</td>
<td>Salamanca, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philip L. McCarthy</td>
<td>Buffalo, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Giampalolo Merlini</td>
<td>Pavia, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fortunato Morabito</td>
<td>Cosenza, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Philippe Moreau</td>
<td>Nantes, France</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gareth J. Morgan</td>
<td>Little Rock, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Nikhil C. Munshi</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hirokazu Murakami</td>
<td>Maebashi, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pellegrino Niesvizky</td>
<td>New York, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ruben Novis</td>
<td>Hollywood, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Susie Offidani</td>
<td>Ancona, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Massimo Orlowski</td>
<td>Houston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Robert Z. Paiva</td>
<td>Pamplona, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bruno Palumbo</td>
<td>Torino, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Antonio Patriarca</td>
<td>Udine, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Francesca Petrucci</td>
<td>Roma, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Maria Teresa Torben</td>
<td>Veje, Denmark</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Felipe Prósper</td>
<td>Pamplona, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Noopur Raje</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>S. Vincent Rajkumar</td>
<td>Rochester, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Paul G. Richardson</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jesús F. San Miguel</td>
<td>Pamplona, Spain</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jatin J. Shah</td>
<td>Houston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kazuyuki Shimizu</td>
<td>Kakkamagahara, Japan</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pieter Sonneveld</td>
<td>Rotterdam, The Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Andrew Spencer</td>
<td>Melbourne, Australia</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Edward A. Stadtmauer</td>
<td>Philadelphia, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A. Keith Stewart</td>
<td>Scottsdale, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evangelos Terpos</td>
<td>Athens, Greece</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patrizia Tosi</td>
<td>Rimini, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Steven P. Teelon</td>
<td>Boston, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Niels Zamagni</td>
<td>Amsterdam, The Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elena Zonder</td>
<td>Bologna, Italy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jeffrey A. Sonja</td>
<td>Detroit, USA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Bart van den Donk</td>
<td>Amsterdam, The Netherlands</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Elena Zweegman</td>
<td>Amsterdam, The Netherlands</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
CONGRESS INFORMATION

VENUE
Auditorium Parco della Musica
Viale de Coubertin, 30
00196 Rome (Italy)
www.auditorium.com

HOW TO REACH
The Auditorium Parco della Musica of Rome is in Viale Pietro de Coubertin, near the Palazzetto dello Sport.
The Auditorium Parco della Musica is in the Flaminio district of Rome, by the Villaggio Olimpico and can be easily reached by public transport:

Bus Routes
- 910, from Termini Station and Piazza Mancini
- 53, from Piazza Mancini and Piazza San Silvestro
- 217, from Viale XVII Olimpiade and Termini Station
- 231, from Piazza Mancini and Piazzale Canestre (in Villa Borghese park), Only weekends
- Linea "M", special bus route between Termini station and Viale Pietro de Coubertin Auditorium stop. From 17h00 - every 15 mins. Last bus from the Auditorium departs at the end of last event.

Tram routes
- 2, from Piazzale Flaminio and Piazza Mancini

Trains
- Metro A line to the Flaminio stop then no.2 tram
- Or the Ferrovia Roma-Nord train to the Piazza Euclide stop

By car
- From the G.R.A. (ring-road around Rome) take the Flaminio Saxa Rubra exit towards Corso di Francia
- From the Lungotevere Flaminio turn off into Viale Tiziano and then again at the Palazzetto dello Sport.

PARKING AREA
There are large car parking facilities by the Auditorium Parco della Musica with designated areas for disabled visitors.

HOTEL AND SHUTTLE INFORMATION DESK
The congress will provide complimentary transfer service between the hotels booked through the IMW hotel booking office and the Auditorium Parco della Musica.
Transfer services will run according to the meeting schedule. One ride in the morning and one in the evening. Please look for detailed shuttle bus schedules in your hotel lobby and on the website (www.imw2015.it).

For further information about hotel accommodation and shuttle bus service provided by the meeting please visit the Hotel and Shuttle Information Desk. The desk is located in the Registration Area and will be open during the following hours:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, September 23, 2015</td>
<td>8.00 - 19.00</td>
</tr>
<tr>
<td>Thursday, September 24, 2015</td>
<td>8.00 - 19.00</td>
</tr>
<tr>
<td>Friday, September 25, 2015</td>
<td>8.00 - 19.00</td>
</tr>
<tr>
<td>Saturday, September 26, 2015</td>
<td>8.00 - 14.00</td>
</tr>
</tbody>
</table>
ROME INFORMATION DESK
For all the information about the city (guided tours, museums, public transportation, etc.), please visit the Rome Information Desk. The desk is located near the bar and will be open during the following hours:

- **Wednesday, September 23, 2015**: 8.00 - 19.00
- **Thursday, September 24, 2015**: 8.00 - 19.00
- **Friday, September 25, 2015**: 8.00 - 19.00
- **Saturday, September 26, 2015**: 8.00 - 14.00

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Registration Categories</th>
<th>Onsite Registration</th>
</tr>
</thead>
<tbody>
<tr>
<td>IMS Members</td>
<td>€ 650,00</td>
</tr>
<tr>
<td>Non-Member</td>
<td>€ 800,00</td>
</tr>
<tr>
<td>Nurses</td>
<td>€ 200,00</td>
</tr>
<tr>
<td>Exhibitors</td>
<td>€ 800,00</td>
</tr>
</tbody>
</table>

The registration fee includes:
- Participation in the scientific sessions
- Access to the exhibition area
- Conference kit
- Attendance certificate
- Lunches
- Coffee breaks
- Welcome reception
- Abstracts e-book

REGISTRATION HOURS

**INDIVIDUALS and EXHIBITORS**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 22</td>
<td>17.00 - 20.00</td>
</tr>
<tr>
<td>Wednesday, September 23</td>
<td>7.00 - 18.00</td>
</tr>
<tr>
<td>Thursday, September 24</td>
<td>7.00 - 18.00</td>
</tr>
<tr>
<td>Friday, September 25</td>
<td>7.00 - 18.00</td>
</tr>
<tr>
<td>Saturday, September 26</td>
<td>7.00 - 13.00</td>
</tr>
</tbody>
</table>

**MEET THE EXPERTS**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 22</td>
<td>8.30 - 20.00</td>
</tr>
<tr>
<td>Wednesday, September 23</td>
<td>7.00 - 18.00</td>
</tr>
<tr>
<td>Thursday, September 24</td>
<td>7.00 - 18.00</td>
</tr>
<tr>
<td>Friday, September 25</td>
<td>7.00 - 18.00</td>
</tr>
</tbody>
</table>

**NURSE**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 22</td>
<td>17.00 - 20.00</td>
</tr>
<tr>
<td>Wednesday, September 23</td>
<td>7.00 - 10.00</td>
</tr>
</tbody>
</table>

**GROUPS & EXHIBITORS**

<table>
<thead>
<tr>
<th>Date</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 22</td>
<td>8.30 - 16.30</td>
</tr>
</tbody>
</table>

BADGE

Badges and meeting materials will be given at the counters in the registration area (ground floor of the Auditorium Parco della Musica). Remember to print and to bring with you in Rome the invitation letter and the badge barcode you received in the “Registration Info” automatic e-mail.

All registered participants, speakers, exhibitors and press staff, will be given a badge which must be worn in order to be admitted to the scientific sessions.

Badge is mandatory to enter the congress area.

A self-printing system will be available in the Registration Area. Delegates, nurses and exhibitors will be able to collect their badges simply by having their personal barcode scanned by the optical reader at the self-printing machines.

Speakers and press staff are kindly requested to collect their badges at the Registration desk.

The barcode on the badge stores the following personal information: name, surname, country and email address provided at the time of registration. It can be used by exhibitors to register visitors to their booths and to send additional information on their products and services.
ATTENDANCE CERTIFICATE
Delegates, nurses and speakers will be able to collect the attendance certificates by having their personal barcode read at the self-printing machines. The service will be available from September 23, 2015 evening.

CLOAKROOM AND LUGGAGE
In the cloakroom you can leave your belongings free of charge. The cloakroom is located in the Registration Area and will be open at the following hours:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, September 23, 2015</td>
<td>6.30 - 21.30</td>
</tr>
<tr>
<td>Thursday, September 24, 2015</td>
<td>6.30 - 20.00</td>
</tr>
<tr>
<td>Friday, September 25, 2015</td>
<td>6.30 - 20.00</td>
</tr>
<tr>
<td>Saturday, September 26, 2015</td>
<td>6.30 - 14.00</td>
</tr>
</tbody>
</table>

CATERING
Lunches, coffee breaks and welcome cocktail are included in the registration fee. No coupon is needed.

<table>
<thead>
<tr>
<th>Date</th>
<th>Lunch</th>
<th>Coffee Break</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, September 23, 2015</td>
<td>13.00 - 14.00</td>
<td>16.00 - 16.30</td>
</tr>
<tr>
<td>Thursday, September 24, 2015</td>
<td>10.20 - 10.50</td>
<td>12.20 - 13.20</td>
</tr>
<tr>
<td>Friday, September 25, 2015</td>
<td>10.20 - 10.50</td>
<td>12.20 - 13.20</td>
</tr>
<tr>
<td>Saturday, September 26, 2015</td>
<td>10.15 - 10.30</td>
<td>13.00 - 14.00</td>
</tr>
</tbody>
</table>

The IMW Welcome Cocktail is scheduled on September 23, 2015 from 19.30 to 21.30 in the Cavea area. It is an outdoor standing buffet dinner.

The bar is located near the Exhibition Area and it will be open at the following hours:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, September 22, 2015</td>
<td>8.00 - 19.30</td>
</tr>
<tr>
<td>Wednesday, September 23, 2015</td>
<td>6.30 - 19.30</td>
</tr>
<tr>
<td>Thursday, September 24, 2015</td>
<td>6.30 - 19.30</td>
</tr>
<tr>
<td>Friday, September 25, 2015</td>
<td>6.30 - 19.30</td>
</tr>
<tr>
<td>Saturday, September 26, 2015</td>
<td>6.30 - 19.30</td>
</tr>
</tbody>
</table>

Direct payment in Euro.

PHOTOS AND AUDIO-VIDEO RECORDING
Individual photos and audio-video recording are prohibited. Only authorized staff can provide photos and audio-video recording services.

INTERNET ACCESS
WiFi is available inside the Congress Area as follows:
ID: IMW2015
PASSWORD: TAKEDA2015
An internet point will be available in the Exhibition area (see floor plan).

CASH WITHDRAWAL
A cash dispenser is located at the entrance of the meeting venue. Onsite payments should be made in Euro.

EXHIBITION
The exhibition area will be open at the following hours:

<table>
<thead>
<tr>
<th>Date</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wednesday, September 23, 2015</td>
<td>9.00 - 21.00</td>
</tr>
<tr>
<td>Thursday, September 24, 2015</td>
<td>8.00 - 19.00</td>
</tr>
<tr>
<td>Friday, September 25, 2015</td>
<td>8.00 - 19.00</td>
</tr>
<tr>
<td>Saturday, September 26, 2015</td>
<td>8.00 - 14.00</td>
</tr>
</tbody>
</table>
### EXHIBITION AREA

<table>
<thead>
<tr>
<th>Exibitor</th>
<th>Area</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen</td>
<td>B1</td>
</tr>
<tr>
<td></td>
<td>B2</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co.</td>
<td>G</td>
</tr>
<tr>
<td>Binding Site</td>
<td>C1-D1</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>C2-D2</td>
</tr>
<tr>
<td>Doctors.MD Ltd.</td>
<td>8</td>
</tr>
<tr>
<td>Janssen</td>
<td>F</td>
</tr>
<tr>
<td>Karyopharm Therapeutics Inc.</td>
<td>3</td>
</tr>
<tr>
<td>Managing Myeloma</td>
<td>2</td>
</tr>
<tr>
<td>Oslo Myeloma</td>
<td>4-5-6-E1</td>
</tr>
<tr>
<td>Oslo Myeloma Hospitality Suite</td>
<td>E2</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>A1</td>
</tr>
<tr>
<td>Takeda Oncology Staff Office</td>
<td>A2</td>
</tr>
<tr>
<td>3rd International Myeloma Workshop</td>
<td>9</td>
</tr>
</tbody>
</table>

### MEETING ROOMS

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amgen</td>
<td>Room B</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co.</td>
<td>Room B</td>
</tr>
<tr>
<td>Bristol-Myers Squibb Co.</td>
<td>Room E</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>Room C</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>Room D</td>
</tr>
<tr>
<td>Janssen</td>
<td>Room A</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>Studio 1</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>Studio 2</td>
</tr>
<tr>
<td>Takeda Oncology</td>
<td>Studio 3</td>
</tr>
</tbody>
</table>

### SANTA CECILIA HALL

- Plenary Session

### FLOOR PLAN

- **1st Floor Poster Area**
- **Poster Help Desk**
- **Self Registration Area**
- **Entrance**
- **Catering Area**
- **Teatro Studio Hall**
- **Nursing Symposium**
- **Meet the Experts Sessions**
- **Exhibition Area**
- **Meeting Rooms**
- **Sponsor Rooms**
LANGUAGE
The Workshop will be in English with no simultaneous translation into other languages.

ITALIAN CME CREDITS
Two Italian CME applications have been submitted as follows:

Main program (September 23-24-25-26, 2015):
- Provider Studio ER Congressi SRL: ID 828-132558.
- No. 11 CME credits for Physicians (Clinical Biochemistry, Cardiac Surgery, Cardiology, General Surgery, Palliative Care, Haematology, Epidemiology, Pharmacology and Clinical Toxicology, Medical Genetics, Geriatrics, Laboratory of Medical Genetics, General Medicine, Internal Medicine, Nuclear Medicine, Microbiology and Virology, Oncology, Clinical Pathology, Radiotherapy), Biologists, Medical Laboratory Scientists, Nurses and Chemists.
- Educational objective: “guidelines-protocols-procedures”. Poster sessions, meet the experts sessions, sponsored symposia are not included in the submission.

In order to claim for credits attendees should:
- wear a magnetic tag in order to register their presence inside the Plenary Hall. Please ask for it at the CME Registration Desk;
- attend at least the 80% of the submitted program;
- complete the CME questionnaire. Please ask for it at the CME Registration Desk on Saturday 26, 2015 morning;
- return the magnetic tag and the questionnaire at the end of the meeting.

Nursing Symposium (September 23, 2015):
- Provider Studio ER Congressi SRL: ID 828-132580.
- No. 5 CME credits for Nurses.
- Educational objective: “guidelines-protocols-procedures”.

In order to claim for credits nurses should:
- sign the attendance list at the entrance of the Teatro Studio Hall;
- attend the 100% of the Nursing Symposium;
- complete the CME questionnaire. Please ask for it at the entrance of the Teatro Studio Hall on Wednesday 23, 2015 afternoon;
- return the questionnaire at the end of the Nursing Symposium.

CME certificates will be sent after the meeting by email.

SCIENTIFIC INFORMATION

EBAH CME CREDITS
The program of the “15th International Myeloma Workshop” has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 25 CME credits for Physicians, Biologists, Medical Laboratory Scientists, Nurses and Chemists. EBAH Credit Points will be awarded for the Plenary Sessions and Meet the Experts Sessions.

To request credits, please fill out the form and return it to the registration desk at the end of the meeting.

We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: http://ebach.org even on site.

TEXT MESSAGE AND VOTING FLAGS
Text message system is available during the whole meeting in order to improve discussion during the plenary sessions. Voting green/red flags for the Debate sessions are available inside the Plenary Hall in order to improve the interaction between attendees and speakers.

POSTER AREA
Poster sessions will take place in the Poster Area.
Opening hours:

<table>
<thead>
<tr>
<th>Installation</th>
<th>Wednesday, September 23, 2015 14.00 - 19.00</th>
</tr>
</thead>
<tbody>
<tr>
<td>Viewing</td>
<td>Thursday, September 24, 2015 8.00 - 20.00</td>
</tr>
<tr>
<td></td>
<td>Friday, September 25, 2015 8.00 - 20.00</td>
</tr>
<tr>
<td></td>
<td>Saturday, September 26, 2015 8.00 - 13.00</td>
</tr>
<tr>
<td>Best Poster Discussion</td>
<td>Thursday, September 24, 2015 18.40 - 19.40</td>
</tr>
<tr>
<td></td>
<td>Friday, September 25, 2015 18.40 - 19.40</td>
</tr>
<tr>
<td>Tear off</td>
<td>Saturday, September 26, 2015 13.00 - 14.00</td>
</tr>
</tbody>
</table>

Posters should be installed/removed during the indicated set-up time (see above). Materials to hang posters will be available at the poster area. The Congress provides one board for each poster, the author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors. There will be a poster helpdesk in the poster area where staff will be happy to assist you.

Posters will be on display in the Poster Area for three days and will be open for viewing on Thursday, Friday and Saturday.

The best posters will be presented during Poster walking session on Thursday and Friday from 18.40 to 19.40.
**SLIDE CENTER/SPEAKERS' AREA**

Opening hours:

- **Wednesday, September 23, 2015**: 7.30 - 19.00
- **Thursday, September 24, 2015**: 6.30 - 19.00
- **Friday, September 25, 2015**: 6.30 - 19.00
- **Saturday, September 26, 2015**: 6.30 - 14.00

**MEET THE EXPERTS SESSIONS**

There will be four Meet the Experts Sessions on September 24, September 25 and September 26 from 7.00 to 8.00. The registration is not included in the Registration Fee. It costs Euro 25,00 per day (VAT included). Each session is restricted to 25 participants.

Preregistration for these sessions is necessary. Tickets can also be purchased during registration hours at the Registration Desk if still available.

All Meet the Expert Sessions are located in TEATRO STUDIO HALL as follows:

<table>
<thead>
<tr>
<th>Thursday, Sep 24, 2015</th>
<th>Friday, Sep 25, 2015</th>
<th>Saturday, Sep 26, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diagnostic Criteria</td>
<td>Monoclonal Gammapathy of Undetermined Significance - Smoldering Multiple Myeloma</td>
<td>Amyloid Light-chain Amyloidosis</td>
</tr>
<tr>
<td>Xavier Leleu, Elena Zamagni</td>
<td>Luca Baldini, Brian G.M. Durie</td>
<td>Raymond L. Comenzo, Fortunato Morabito</td>
</tr>
<tr>
<td>GREEN ROOM</td>
<td>GREEN ROOM</td>
<td>GREEN ROOM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newly Diagnosed Multiple Myeloma Patients &lt; 65 years, High-risk Patients: How to treat</td>
<td>Newly Diagnosed Multiple Myeloma Fit Patients &gt; 65 years: How to treat</td>
<td>Waldenström Macroglobulinemia</td>
</tr>
<tr>
<td>Michele Cavo, Francesca Patiranca</td>
<td>Ruben Nesiak, Massimo Offidani</td>
<td>Pellegino Musto, Steven P. Trean</td>
</tr>
<tr>
<td>RED ROOM</td>
<td>RED ROOM</td>
<td>RED ROOM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lombardi Macroglobulinemia</td>
<td>Noopur Raje, Patrizia Tosi</td>
<td>Supportive Care</td>
</tr>
<tr>
<td>Michele Cavo, Francesca Patiranca</td>
<td>Laura Balducci, Maria Teresa Petrucci</td>
<td>Joan Barik</td>
</tr>
<tr>
<td>BLUE ROOM</td>
<td>BLUE ROOM</td>
<td>BLUE ROOM</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Relapsed/Refractory Multiple Myeloma 1-3 Previous Lines of Therapy: How to treat</td>
<td>Relapsed/Refractory Multiple Myeloma 4-6 Previous Lines of Therapy: How to treat</td>
<td>Supportive Care</td>
</tr>
<tr>
<td>Faith E. Davies, Francesco Di Raimondo</td>
<td>Alessandro Corso, Barbara Settenreth</td>
<td>Joan Barik, Maria Teresa Petrucci</td>
</tr>
<tr>
<td>YELLOW ROOM</td>
<td>YELLOW ROOM</td>
<td>YELLOW ROOM</td>
</tr>
</tbody>
</table>

**AWARDS**

**WALDENSTRÖM’S AWARD**

Recognition for a lifetime achievement for contributions to multiple myeloma research. The award is named for Professor Jan Waldenström, who was a pioneer in treating blood cancers. The award presentation is scheduled on September 23, 2015 at 18.00 in the Plenary Session.

**RISING STARS AWARD**

The Scientific Committee selected the best four abstracts submitted by authors under 35 years of age. These abstracts will be presented in plenary session on Saturday from 9.00 to 10.00. The authors will receive a check of Euro 5,000,00 onsite.

**BART BARLOGIE YOUNG INVESTIGATOR AWARD**

In recognition to the outstanding research developed by Dr. Bart Barlogie in the field of multiple myeloma, the IMS Board of Directors decided to establish the Bart Barlogie Young Investigator Award. This award is aimed at formally recognizing and stimulating excellence in myeloma research. The Young Investigator Award will be given to an investigator under the age of 40 years in recognition of their research in the myeloma field. An Award of US $25,000 by the IMS will be given at each of the International Myeloma Workshops, beginning with Rome in September 2015.

The award presentation is scheduled on September 26, 2015 at 10.00 in the Plenary Session.

**IMW APP**

A special mobile app has been developed for this congress in which you can find the entire program and further information. Use the app to find sessions of interest, create your own program, find and read all the abstracts. Download the “IMW2015” app from the Apple App store or Google-Play.

**OFFICIAL WEBSITE**

www.imw2015.it

**CHANGES**

Parts of the program may be changed without prior notice.
SERVICES PROVIDED

<table>
<thead>
<tr>
<th>Service</th>
<th>Name</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abstract e-book</td>
<td>Congress Kit</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Cash Withdrawal</td>
<td>Cash Dispenser</td>
<td>Meeting Venue Entrance</td>
</tr>
<tr>
<td>City Information</td>
<td>Rome Information Desk</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>Cloakroom and Luggage</td>
<td>Cloakroom</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Internet</td>
<td>Internet Point</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>WiFi</td>
<td>Wireless Internet</td>
<td>Throughout the Venue</td>
</tr>
<tr>
<td>Exhibition Information</td>
<td>Exhibitor Help Desk</td>
<td>Exhibition Area</td>
</tr>
<tr>
<td>Hotel and Shuttle Information</td>
<td>Hotel and Shuttle Information Desk</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Meet the Experts Tickets</td>
<td>Registration Desk</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Vatican Museum Tickets</td>
<td>Registration Area</td>
<td>Registration Area</td>
</tr>
<tr>
<td>Poster Information</td>
<td>Poster Help Desk</td>
<td>Poster Area</td>
</tr>
</tbody>
</table>

OPENING HOURS

<table>
<thead>
<tr>
<th>Service</th>
<th>Tuesday, September 22, 2015</th>
<th>Wednesday, September 23, 2015</th>
<th>Thursday, September 24, 2015</th>
<th>Friday, September 25, 2015</th>
<th>Saturday, September 26, 2015</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration Area</td>
<td>8.30 - 20.00</td>
<td>6.30 - 20.00</td>
<td>6.30 - 20.00</td>
<td>6.30 - 14.00</td>
<td></td>
</tr>
<tr>
<td>Slide Center/Speakers' Area</td>
<td>7.30 - 19.00</td>
<td>6.30 - 19.00</td>
<td>6.30 - 19.00</td>
<td>6.30 - 14.00</td>
<td></td>
</tr>
<tr>
<td>Cloakroom</td>
<td>6.30 - 21.30</td>
<td>6.30 - 20.00</td>
<td>6.30 - 20.00</td>
<td>6.30 - 14.00</td>
<td></td>
</tr>
<tr>
<td>Exhibition Area</td>
<td>9.00 - 21.00</td>
<td>8.00 - 19.00</td>
<td>8.00 - 19.00</td>
<td>8.00 - 14.00</td>
<td></td>
</tr>
<tr>
<td>Poster Area</td>
<td>8.00 - 20.00</td>
<td>8.00 - 20.00</td>
<td>8.00 - 20.00</td>
<td>8.00 - 13.00</td>
<td></td>
</tr>
<tr>
<td>Rome Information Desk</td>
<td>8.00 - 19.00</td>
<td>8.00 - 19.00</td>
<td>8.00 - 19.00</td>
<td>8.00 - 14.00</td>
<td></td>
</tr>
<tr>
<td>Hotel and Shuttle Info Desk</td>
<td>8.00 - 19.00</td>
<td>8.00 - 19.00</td>
<td>8.00 - 19.00</td>
<td>8.00 - 14.00</td>
<td></td>
</tr>
</tbody>
</table>

15TH INTERNATIONAL MYELOMA WORKSHOP

SEPTEMBER 23 - 26, 2015

Rome, Auditorium Parco della Musica

www.imw2015.com
**Wednesday, September 23, 2015**

**OPENING CEREMONY**

**ROBERT KYLE LECTURE**
Access to Innovation and Quality of Care in the Context of Economic Constraints: a Challenge for Healthcare

**GENOMICS AND MICROENVIRONMENT**

**NOVARTIS ONCOLOGY SPONSORED SYMPOSIUM**

**Lunch**
Thursday, September 24, 2015

**MEET THE EXPERTS**
Simultaneous sessions in four rooms

**GREEN ROOM**
07.00-08.00  Diagnostic Criteria
Xavier Leleu, Elena Zamagni

07.00-08.00  Newly Diagnosed Multiple Myeloma Patients < 65 years,
High-risk Patients: How to treat
Michele Cavo, Francesca Patriarca

07.00-08.00  Newly Diagnosed Multiple Myeloma Patients < 65 years,
Low-risk Patients: How to treat
Mario Boccadoro, Andrzej J. Jakubowiak

07.00-08.00  Relapsed/Refractory Multiple Myeloma 1-3 Previous Lines of Therapy: How to treat
Faith E. Davies, Francesco Di Raimondo

**RED ROOM**
07.00-08.00  Newly Diagnosed Multiple Myeloma Patients < 65 years,
High-risk Patients: How to treat
Michele Cavo, Francesca Patriarca

**BLUE ROOM**
07.00-08.00  Newly Diagnosed Multiple Myeloma Patients < 65 years,
Low-risk Patients: How to treat
Mario Boccadoro, Andrzej J. Jakubowiak

**YELLOW ROOM**
07.00-08.00  Relapsed/Refractory Multiple Myeloma 1-3 Previous Lines of Therapy: How to treat
Faith E. Davies, Francesco Di Raimondo

**SANTA CECELIA HALL**
Chairmen: Michele Cavo, Angelo Maiolino
08.00-08.20  Optimal Induction
Michel Attal

08.20-08.40  Single-tandem Transplantation
Hermann Einsele

08.40-09.00  Optimal Consolidation Therapy
Michele Cavo

09.00-09.20  Transplant Eligible Maintenance
Philip L. McCarthy

09.20-09.40  Ongoing Studies/Open Questions in America
Sergio A. Giralt

09.40-10.00  Ongoing Studies/Open Questions in Europe
Roman Hájek

10.00-10.20  Ongoing Studies/Open Questions in Asia Pacific
Jian Hou
PRIME ONCOLOGY SPONSORED SYMPOSIUM
Building on the Foundation of Proteasome Inhibition in Multiple Myeloma
Chairman: Mario Boccadoro

10.50-10.52 Welcome and Introduction
Mario Boccadoro

10.52-10.55 “Myeloma Guru” Questions

10.55-11.10 Targeting the Ubiquitin-proteasome System in Multiple Myeloma: Examining the Roots of Success
Paul G. Richardson

11.10-11.15 “Myeloma Guru” Questions

11.15-11.30 Challenges and Solutions with First-generation Proteasome Inhibition: Practical Strategies
Maria-Victoria Mateos

11.30-11.35 “Myeloma Guru” Questions

11.35-11.50 Second-generation Proteasome Inhibition: What a Difference a Generation makes
Mario Boccadoro

11.50-11.55 “Myeloma Guru” Questions

11.55-12.10 Implications of Oral Proteasome Inhibition: Impact on Patients
Shaji K. Kumar

12.10-12.20 Audience Questions and Faculty Panel Discussion

12.20 Adjourn

12.20-13.20 Lunch

AMGEN SPONSORED SYMPOSIUM
Delving Into the Deep – Advances in the Treatment of Multiple Myeloma in 2015
Chairman: Antonio Palumbo

13.20-13.25 Welcome and Introduction
Antonio Palumbo

13.25-13.42 Reaching Beyond Overall Response in Patients with Multiple Myeloma
Philippe Moreau

13.42-13.59 Two-drug Combinations in the Treatment of Multiple Myeloma
Evangelos Terpos

13.59-14.16 Three-drug Combinations in the Treatment of Multiple Myeloma
A. Keith Stewart

14.16-14.33 The Evolving Role of Proteasome Inhibition in Multiple Myeloma
Antonio Palumbo

14.33-14.48 Panel Discussion

14.48-14.50 Summary and Close
Antonio Palumbo

RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS
Chairmen: Joan Bladé, Sundar Jagannath

14.50-15.10 How I treat Relapsed/Refractory Multiple Myeloma, Sequence Strategy, Patient Selection
Robert Orlowski

15.10-15.30 How I treat Refractory Disease and Extramedullary Disease
Joan Bladé

15.30-15.50 How I treat Serious Adverse Events
Heinz Ludwig

15.50-16.10 How I use Bone Support
Evangelos Terpos

16.10-16.30 How I use Supportive Care and Palliation
Francesca Gay
### ALLOGENEIC TRANSPLANTATION AND NOVEL AGENTS

Chairmen: Nicolaus Kroeger, Andrew Spencer

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17.00-17.20</td>
<td>Significance of Allogenic Stem Cell Transplantation</td>
<td>Nicolaus Kroeger</td>
</tr>
<tr>
<td>17.20-17.40</td>
<td>Selective Histone Deacetylase Inhibitor</td>
<td>Noopur Raje</td>
</tr>
<tr>
<td>17.40-18.00</td>
<td>Inhibitors (KPT – KSP)</td>
<td>Jatin J. Shah</td>
</tr>
<tr>
<td>18.00-18.20</td>
<td>Inhibitors (BCL2 - MCL1 - CDK)</td>
<td>Lawrence Boise</td>
</tr>
<tr>
<td>18.20-18.40</td>
<td>Targeting Oncogenic Pathways in Myeloma (MEK - PI3K - AKT)</td>
<td>Andrew Spencer</td>
</tr>
</tbody>
</table>

### POSTER SESSION I

Chairman: Nizar J. Bahlis

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chairman</th>
</tr>
</thead>
<tbody>
<tr>
<td>18.40-19.40</td>
<td>Multiple Myeloma Genomics, Diagnosis, Prognosis, Imaging</td>
<td>Nizar J. Bahlis</td>
</tr>
<tr>
<td>18.40-19.40</td>
<td>Multiple Myeloma Therapy in Newly Diagnosed Patients including Transplantation</td>
<td>Andrzej J. Jakubowiak</td>
</tr>
<tr>
<td>18.40-19.40</td>
<td>Epidemiology, QoL, Toxicities, and Other Plasma Cell Dyscrasias</td>
<td>Raymond L. Comenzo</td>
</tr>
</tbody>
</table>

### MEET THE EXPERTS

**Simultaneous sessions in four rooms**

**GREEN ROOM**

- 07.00-08.00 Monoclonal Gammopathy of Undetermined Significance - Smoldering Multiple Myeloma
  - Luca Baldini, Brian G.M. Durie

- 07.00-08.00 Newly Diagnosed Multiple Myeloma Fit Patients > 65 years: How to treat
  - Ruben Niesvizky, Massimo Offidani

**RED ROOM**

- 07.00-08.00 Newly Diagnosed Multiple Myeloma Frail Patients > 65 years: How to treat
  - Sara Bringhen, Sonja Zweegman

**BLUE ROOM**

- 07.00-08.00 Relapsed/Refractory Multiple Myeloma 4-6 Previous Lines of Therapy: How to treat
  - Alessandro Corso, Sundar Jagannath

**YELLOW ROOM**

- 07.00-08.00 Monoclonal Gammopathy of Undetermined Significance – Smoldering Multiple Myeloma
  - Luca Baldini, Brian G.M. Durie

- 07.00-08.00 Newly Diagnosed Multiple Myeloma Fit Patients > 65 years: How to treat
  - Ruben Niesvizky, Massimo Offidani

- 07.00-08.00 Newly Diagnosed Multiple Myeloma Frail Patients > 65 years: How to treat
  - Sara Bringhen, Sonja Zweegman

- 07.00-08.00 Relapsed/Refractory Multiple Myeloma 4-6 Previous Lines of Therapy: How to treat
  - Alessandro Corso, Sundar Jagannath
09.40-10.00  Ongoing Studies/Open Questions in Europe
Monika Engelhardt

10.00-10.20  Ongoing Studies/Open Questions in Asia Pacific
Tadao Ishida

10.20-10.50  Coffee break

**CELGENE CORPORATION SPONSORED SYMPOSIUM**

**The Role of Immunomodulators in the Future Landscape of Multiple Myeloma**
Chairman: Michele Cavo

10.50-10.55  Welcome
Michele Cavo

10.55-11.15  Multiple Myeloma – Coping with a Disrupted Immune Environment
Kenneth C. Anderson

11.15-11.30  Continuous Therapy for Elderly Newly Diagnosed Multiple Myeloma
Thierry Facon

11.30-11.45  Clonal Evolution – Disease Challenges
Gareth J. Morgan

11.45-12.10  IMiD-based Triplet Therapy for Multiple Myeloma
Sagar Lonial

12.10-12.20  Questions and Discussion

12.20-13.20  Lunch

**JANSSEN SPONSORED SYMPOSIUM**

**The Clinical Rationale and Experience with Monoclonal Antibodies in Multiple Myeloma**
Chairmen: Antonio Palumbo, Jesús F. San Miguel

13.20-13.30  Understanding the Biological Rationale
Fabio Malavasi

13.30-13.40  What do the Preclinical Data tell us?
Sagar Lonial

13.40-13.50  Panel Discussion

**Current Clinical Experience with anti-CD38 Monoclonal Antibodies:**

13.50-14.00  Single Agent Activity
Jesús F. San Miguel

14.00-14.10  Combination Studies
Antonio Palumbo

14.10-14.30  Practical Management Consideration for Patients Receiving anti-CD38 Monoclonal Antibodies
Philippe Moreau

14.30-14.50  Panel Discussion

**IMMUNOTHERAPY**

Chairmen: David E. Avigan, Thierry Facon

14.50-15.10  SLAMF7 Combinational Monoclonal Antibodies Therapy
Thierry Facon

15.10-15.30  CD38, Novel Monoclonal Antibodies Targets, Immunotoxin
Thomas G. Martin

15.30-15.50  PD1 - PDL1 - Vaccine
David E. Avigan

15.50-16.10  CAR-T
Edward A. Stadtmauer

16.10-16.30  Bispecific Monoclonal Antibodies
Jeffrey A. Zonder
MEET THE EXPERTS
Simultaneous sessions in four rooms

07.00-08.00  Amyloid Light-chain Amyloidosis
Raymond L. Comenzo, Fortunato Morabito

07.00-08.00  Waldenström Macroglobulinemia
Pellegrino Musto, Steven P. Treon

07.00-08.00  Bone Disease
Noopur Raje, Patrizia Tosi

07.00-08.00  Supportive Care
Joan Bladé, Maria Teresa Petrucci

DEBATE
Chairmen: Brian G.M. Durie, Antonio Palumbo

08.00-08.15  Biomarker to change Therapy Minimal Residual Disease/Imaging vs FISH/Age - in Favor of Minimal Residual Disease/Imaging
C. Ola Landgren

08.15-08.30  Biomarker to change Therapy Minimal Residual Disease/Imaging vs FISH/Age - in Favor of FISH/Age
Pieter Sonneveld

08.30-08.45  Can we cure Multiple Myeloma by 2020? Yes
Bart Barlogie

08.45-09.00  Can we cure Multiple Myeloma by 2020? No
Hartmut Goldschmidt

RISING STARS AWARD
Chairmen: Brian G.M. Durie, Antonio Palumbo

09.00-09.15  RS-001
Hedgehog Pathway over Expression Identifies Myeloma Patients with worse Prognosis
Marina Martello
09.15-09.30 RS-002
Preclinical Analysis of Feasibility and Efficacy of CSI Directed CART cell Therapy in Multiple Myeloma in the Autologous Setting
Sophia Danhof

09.30-09.45 RS-003
Carfilzomib and Dexamethasone in Untreated Symptomatic Multiple Myeloma
Peter Forsberg

09.45-10.00 RS-004
Ribosomal dysfunction in AL amyloidosis: Gene Expression Profile Meta-Analysis
Fedor Kryukov

BART BARLOGIE YOUNG INVESTIGATOR AWARD
10.00-10.15 Chairmen: Kenneth C. Anderson, Bart Barlogie, Joan Bladé

10.15-10.30 Coffee break EXHIBITION AREA

DEBATE SANTA CECILIA HALL
Chairmen: Mario Boccadoro, Hermann Einsele

10.30-10.45 How to incorporate the Newest Agents Combo vs Sequence - in Favor of Combo
Faith E. Davies

10.45-11.00 How to incorporate the Newest Agents Combo vs Sequence - in Favor of Sequence
Shaji K. Kumar

PLENARY ABSTRACT SESSION SANTA CECILIA HALL
Chairmen: Mario Boccadoro, Hermann Einsele

11.00-11.15 OP-001
A Meta-Analysis Investigating the Impact of Minimal Residual Disease (MRD) Status on Survival Outcomes in Patients with Multiple Myeloma (MM) who Achieve Complete Response (CR)
Nikhil Munshi

11.15-11.30 OP-002
Genome-scale CRISPR-Cas9 Knockout Studies to characterize the Mechanisms of Myeloma Cell Treatment Resistance
Yiguo Hu

11.30-11.45 OP-003
Carfilzomib (CFZ), Lenalidomide (LEN), and Dexamethasone (DEX) (KRd) combined with Autologous Stem Cell Transplant (ASCT) shows Improved Efficacy compared with KRd without ASCT in Newly Diagnosed Multiple Myeloma (NDMM)
Andrzej J. Jakubowiak

11.45-12.00 OP-004
Early Mortality in Elderly Patients with Newly Diagnosed Multiple Myeloma Treated with Novel Agents
Alessandra Larocca

12.00-12.15 OP-005
Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study (NCT02103335) of Pomalidomide (POM), Marizomib (MRZ, NPI-0052), and Dexamethasone (DEX) in Patients with Relapsed and Refractory Multiple Myeloma (MM); Study NPI-0052-107 Preliminary Results
Andrew Spencer

12.15-12.30 OP-006
The Genomic and Transcriptional Landscape of Waldenström’s Macroglobulinemia Impacts Disease Presentation, Overall Survival and Therapeutic Response
Zachary Hunter

12.30-13.00 CLOSING CEREMONY SANTA CECILIA HALL

13.00-14.00 Lunch EXHIBITION AREA
2nd MYELOMA NURSING SYMPOSIUM

Wednesday, September 23, 2015

10.45-11.00  Welcome and Open
Elena Ponticelli, Tracy King

MANAGING TOXICITIES AND SYMPTOMS
TEATRO STUDIO HALL
Chairmen: Daniela Klarica, Tiffany Richards

11.00-11.40  Keeping Patients on Treatment: Management of Toxicities Related to New Therapies and Challenges of Symptom Management Research
Beth Faiman

11.40-12.00  Toxicities Associated with SQ Bortezomib: an Update of the Italian Experience
Alessandra Malfitano

12.00-12.20  Evidenced Based Practice for Central Line Care: Impact of New Therapies on Utilization of Venous Access Devices by Patients with Myeloma
Annalisa Bernardini

12.20-12.40  The Devils in the Dex: the Experience of High Dose Dexamethasone and Implications for PRO Tool Development
Tracy King

12.40-13.00  “We are the Nurses all the Time”: the Experience and Supportive Care Needs of the Family in the Era of Novel Myeloma Therapies
Monica Morris

13.00-14.00  Lunch
ABSTRACT SESSION

Chairman: Beth Faiman

14.00-14.20  NO-001
Lack of Health Maintenance Exams and Risk: an Internet-Based Survey on Health Maintenance and Preventive Care Patterns in Patients with Myeloma
Joseph D. Tariman

14.20-14.40  NO-002
A CAM do Approach: the attitudes, Use and Disclosure of the Use of Complementary and Alternative Medicine (CAM) in those with myeloma
Tracy King

14.40-15.00  NO-003
A Pilot Placebo Controlled Study to Estimate the Effect Size of Glutamine to Prevent Peripheral Neuropathy in Multiple Myeloma
Beth Faiman

15.00-15.20  NO-004
Development of a Nurse Led Community based Bortezomib Program for Multiple Myeloma (MM)
Daniela Klarica

15.20-15.40  NO-005
Aplasia on the own Couch at Home in Multiple Myeloma Patients after Autologous Stem Cell Transplantation
Iris Agreiter

15.40-16.00  NO-006
Cellular Immunotherapy for Myeloma using Chimeric Antigen Receptor Modified T Cells (CARs)
Patricia Mangan

16.00-16.30  Coffee break

NURSING PLENARY

Chairman: Monica Morris

16.30-17.15  Integrating Myeloma Genomics into Nursing Practice: Patient Education and Shared Decision Making
Joseph D. Tariman

17.15-17.35  Formation of International Nurses Society
Tracy King

17.35-17.45  IMW 2017 New Delhi Summary and Close
Elena Ponticelli, Tracy King

GENERAL INFORMATION OF THE NURSING SYMPOSIUM

VENUE
Teatro Studio Hall
Auditorium Parco della Musica
Viale de Coubertin, 30
00196 Rome (Italy)
www.auditorium.com

POSTER
Poster session will take place in the Teatro Studio Hall:

Installation
Wednesday, September 23, 2015  9.30 - 10.30  Teatro Studio Hall

Viewing
Wednesday, September 23, 2015  10.30 - 18.00  Teatro Studio Hall
Thursday, September 24, 2015  8.00 - 20.00  Poster Area
Friday, September 25, 2015  8.00 - 20.00  Poster Area
Saturday, September 26, 2015  8.00 - 13.00  Poster Area
Saturday, September 26, 2015  13.00 -14.00  Poster Area

Posters should be installed in Teatro Studio Hall, on the back of the room in order to make posters available during the Nursing Symposium. At the end of the symposium, the Organizing Secretariat staff will move posters in the Poster Area of the meeting.

Materials to hang posters with will be available in Teatro Studio Hall. The Congress provides one board for each poster. The author is responsible for hanging and for removing the poster. Please note that the organisers do not take any responsibility for returning uncollected material to the authors. There will be a poster helpdesk where staff will be happy to assist you.
| BP-001 | J. Keats | INTERIM ANALYSIS OF THE MMRF COMMPASS STUDY: COMPREHENSIVE CHARACTERIZATION OF MULTIPLE MYELOMA PATIENTS AT DIAGNOSIS REVEALS DISTINCT MOLECULAR SUBTYPES AND CLINICAL OUTCOMES |
| BP-002 | M.F. Kaiser | MOLECULAR RISK STRATIFICATION OF 1,036 CASES FROM THE NCRI MYELOMA XI TRIAL USING THE ALL-MOLECULAR DIAGNOSTIC TOOL MYMAP (MYELOMA MLPA AND TRANSLOCATION PCR) |
| BP-003 | R. Kaedbey | NONINVASIVE DIAGNOSIS OF ACTIONABLE MUTATIONS BY DEEP SEQUENCING OF CIRCULATING CELL FREE DNA (CFDNA) IN MULTIPLE MYELOMA (MM) |
| BP-004 | G. Marzocchi | RARE HIGH RISK IGH TRANSLOCATIONS IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): CYTOGENETIC CHARACTERIZATION AND RELEVANCE ON PROGNOSIS |
| BP-005 | J. Sawyer | JUMPING TRANSLocations OF 1q12 IN MULTIPLE MYELOMA: UNEXPECTED INTRA-CLONAL HETEROGENEITY OF COPY NUMBER ABERRATIONS IN THE 1q21-31 REGION |
| BP-006 | S. Manier | CIRCULATING EXOSOMAL MICRORNAS ARE CRITICAL PROGNOSTIC MARKERS INDEPENDENT OF CYTOGENETICS AND INTERNATIONAL STAGING SYSTEM IN MULTIPLE MYELOMA |
| BP-008 | M. Van Duin | GENE EXPRESSION PROFILE OF MULTIPLE MYELOMA PATIENTS WITH POOR RESPONSE TO BORTEZOMIB INDUCTION THERAPY IN THE HOVON65/GMMG-HD4 STUDY |
| BP-009 | A.C. Rawstron | THE IMPACT OF NORMAL PLASMA CELL RECOVERY ON PROGRESSION-FREE AND OVERALL SURVIVAL IN MYELOMA PATIENTS AFTER ASCT |
| BP-010 | H.E. Johnsen | MULTIPLE MYELOMA SUBTYPING THAT ASSOCIATES NORMAL B-CELL SUBSET PHENOTYPES, DO CORRELATE TO DISEASE STAGE AND PROGNOSIS - INDICATION OF REVERSIBLE PHENOTYPIC PLASTICITY AS A HALLMARK |
USEFULNESS OF WHOLE-BODY DIFFUSION-WEIGHTED MRI (WB-DWI) WITH APPARENT DIFFUSION COEFFICIENT (ADC) IN THE DIFFERENTIATION OF MONOCLONAL GAMMAPATHIES: A PROSPECTIVE STUDY OF 34 PATIENTS WITH MULTIPLE MYELOMA

TARGETED SEQUENCING OF RELAPSED/REFRACTORY MYELOMA PATIENTS IDENTIFIES AN ENRICHMENT OF MUTATIONS IN MAPK AND CEREBLON PATHWAYS

MINIMAL RESIDUAL DISEASE IN TRANSPLANT INELIGIBLE MYELOMA PATIENTS: RESULTS FROM THE UK MEL-2017 TRIAL

IMPROVED PROGNOSTIC IMPACT OF MULTIPLE MYELOMA BY A SYSTEMATIC COMBINATION OF GENETIC CLASSIFIERS WITH INCOMPLETE RESULTS IN PREDICTION OF HIGH-AND LOW-RISK MULTIPLE MYELOMA

RELATIONSHIP BETWEEN PRESENCE OF OSSIFYING LESIONS, CYTOGENETIC FEATURES AND BONE MARROW MYELOMA LEVELS OF ROLE OF CHEMOKINE (C-C MOTIF) LIGAND 20 AS A NEW MARKER OF BONE DISEASE

PROGNOSTIC IMPACT OF CIRCULATING PLASMA CELLS ON SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA

ASSESSMENT OF BIOCHEMICAL RESPONSE FOR MULTIPLE MYELOMA (MM) PATIENTS TREATED WITH DARatumumab

WHOLE-EXOME SEQUENCING OF MULTIPLE MYELOMA REVEALS DIVERSE MUTATIONAL LOAD IN DIFFERENT EMPHASIS

MYC PROTEIN EXPRESSION IN MULTIPLE MYELOMA: CLINICOPATHOLOGICAL FEATURES AND PROGNOSTIC IMPACT

THE SPECTRUM AND CLINICAL IMPACT OF EPIGENETIC MODIFIER MUTATIONS IN MULTIPLE MYELOMA

MORNING URINE AS AN ALTERNATIVE TO 24-HOUR URINE ELECTROPHORESIS: A RETROSPECTIVE, MULTICENTER STUDY

REVISED INTERNATIONAL STAGING SYSTEM APPLIED TO JAPANESE PATIENTS: A MULTICENTER RETROSPECTIVE COLLABORATIVE STUDY OF THE JAPANESE SOCIETY OF MYELOMA

BODY FAT, PERCENTAGE AND DISTRIBUTION AS PREDICTIVE FACTORS FOR TREATMENT RESPONSE IN MULTICLASS MYELOMA PATIENTS

HEAVY-LIGHT CHAIN ANALYSIS FOR RESPONSE MONITORING IN MULTICLASS MYELOMA PATIENTS: COMPARISON WITH IMMUNOHISTOCHEMICAL, SERUM FREE LIGHT CHAIN, AND MULTICOLOR FLOW-CYTOMETRY ANALYSIS

POSTER SESSION

PO-001 K. M. Korum

PO-002 S. Keppeler

PO-003 R. Kupfer

PO-004 R. De Tulle

PO-005 B. Dalla Piazza

PO-006 M. Grenell

PO-007 H. Caillon

PO-008 X. Agire

PO-009 C. Pawlyk

PO-010 I. Grob

PO-011 P. Bouad

PO-012 S. Otsuki

PO-013 C. Pawlyk

PO-014 I. Grob

PO-015 K. Matsue

POSTER SESSION

PO-016 J. M. Hernandez

PO-017 D. L. Murray

PO-018 A. K. Noska

PO-019 I. Isola

PO-020 J. Straub

PO-021 A. Silva

PO-022 A. Butrym

PO-023 P. Miari

PO-024 S. McAlister

PO-025 M. Fujiwara

PO-026 N. Lee

PO-027 D. Shahriz

PO-028 R. Kumar

PO-029 Y. Yadav

PO-030 E. K. Mai

POSTER SESSION

PO-001 K. M. Korum

PO-002 S. Keppeler

PO-003 R. Kupfer

PO-004 R. De Tulle

PO-005 B. Dalla Piazza

PO-006 M. Grenell

PO-007 H. Caillon

PO-008 X. Agire

PO-009 C. Pawlyk

PO-010 I. Grob

PO-011 P. Bouad

PO-012 S. Otsuki

PO-013 C. Pawlyk

PO-014 I. Grob

PO-015 K. Matsue
PO-031 | H. Takamatsu | COMPARISON OF MINIMAL RESIDUAL DISEASE DETECTION IN MULTIPLE MYELOMA BETWEEN MULTIPARAMETER FLOW CYTOMETRY AND DEEP-SEQUENCING

PO-032 | J. de la Rubia | GAH SCALE IS A SIMPLE, COMPREHENSIVE ASSESSMENT TOOL IN OLDER PATIENTS WITH HEMATOLOGICAL MALIGNANCIES THAT SHOWS MORTALITY PREDICTION CAPACITIES

PO-033 | R. Jiménez | OUTCOME OF PATIENTS WITH EXTRAMEDULLARY PLASMACYTOMAS (EMPS) INCLUDED IN A PHASE III PETHEMA/GEML STUDY OF INDUCTION THERAPY PRIOR AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN MULTIPLE MYELOMA (MM)

PO-034 | P. Pucsiznova | RELATIONSHIP OF SERUM LEVELS OF SELECTED BIOLOGICAL INDICATORS AND CYTOGENETIC ABNORMALITIES IN MULTIPLE MYELOMA

PO-035 | J. Krönke | INFLUENCE OF CRBN, IKZF1, AND IKZF3 EXPRESSION ON OUTCOME IN LENALIDOMIDE TREATED NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

PO-036 | M. Andrade Campos | RESPONSE AND EARLY RELAPSE ASSESSMENT IN MULTIPLE MYELOMA TREATED WITH BORTezOMIB: ROLE OF HEAVY/LIGHT-CHAIN IMMUNEASSAY

PO-037 | M. Itagaki | RISK FACTORS OF DEVELOPING SYMPTOMATIC MYELOMA FROM MGUS: ANALYSIS IN OUR HOSPITAL

PO-038 | G. Barilà | DIFFUSION WEIGHTED WHOLE BODY MRI FOR EARLY EVALUATION OF RESPONSE IN MULTIPLE MYELOMA

PO-039 | S. Pans | MYELOMA BONE LESIONS ON WHOLE-BODY DIFFUSION-WEIGHTED MAGNETIC RESONANCE IMAGING AT 3.0 T: CHARACTERIZATION AND COMPARISON OF APPARENT DIFFUSION COEFFICIENT AND B1000 VALUE ON 2 DIFFERENT MRI PLATFORMS OF THE SAME VENDOR

PO-040 | P. Yadav | RENAL FUNCTION AND AGE AT PRESENTATION AND SERUM FREE LIGHT CHAIN RESPONSE AT POST-INDUCTION PREDICT RENAL OUTCOME

PO-041 | L. Soares Vieira Da Silva | PREVALENCE OF OLIGOCNOAL BANDS IN MULTIPLE MYELOMA PATIENTS WHO ACHIEVED AT LEAST VERY GOOD PARTIAL RESPONSE AFTER TREATMENT WITH STANDARD OR HIGH DOSE CHEMOTHERAPY-FINAL ANALYSIS

PO-042 | M. Andrade Campos | DETECTING EARLY RELAPSE IN MULTIPLE MYELOMA (MM) AFTER ASCT: USEFULNESS OF IMMUNEASSAYS

PO-043 | C. Suriu | ABSOLUTE LYMPHOCYTE COUNT AS A PROGNOSTIC MARKER IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED IN THE ERA OF NOVEL AGENTS

PO-044 | Y.K. Lee | CYTOGENETIC ABNORMALITIES OF UNDETERMINED CLINICAL SIGNIFICANCE CORRELATE WITH POOR PROGNOSTIC FACTORS IN MULTIPLE MYELOMA

PO-045 | D. Ryu | WHOLE-EXOME SEQUENCING AND TRANSCRIPTOME ANALYSIS FOR IG-N MULTIPLE MYELOMA

PO-046 | S. Savary Bélanger | EARLY EVALUATION OF RESPONSE BY SERUM FREE LIGHT CHAIN (FLC) AND HEVYLITE (HLC) IN INTACT IMMUNOGLOBULIN (IgG) MULTIPLE MYELOMA (MM): PREDICTION OF OUTCOME

PO-047 | G. Graziani | ASSESSMENT OF TIME FROM ONSET OF FIRST SYMPTOMS TO THE FINAL DIAGNOSIS OF MULTIPLE MYELOMA (MM) - POSSIBLE RISKS AND FUTURE SOLUTIONS

PO-048 | S. Pans | ASSESSING PROGRESSIVE DISEASE IN MYELOMA PATIENTS WITH WHOLE-BODY DIFFUSION-WEIGHTED IMAGING AT 3.0 T: A PROSPECTIVE IMAGING STUDY COMPARING WHOLE BODY T1-WI, T2-STIR-WI AND LABORATORY FINDINGS

PO-049 | M. Andrade Campos | MYELOMA MULTIPLE (MM) IG SUBTYPE. USEFULNESS OF HEAVYLIGHT IGA/K/IGA QUANTIFICATION FOR DIAGNOSIS AND FOLLOW-UP

PO-050 | W. Willenbacher | LOW BECN1 EXPRESSION PREDICTS IMPROVED OVERALL SURVIVAL IN PATIENTS TREATED WITH IMMUNE-MODULATORY DRUGS FOR MULTIPLE MYELOMA AND IDENTIFIES AUTOANTIBODY INHIBITION AS A PROMISING POTENTIALLY DRUGGABLE NEW THERAPEUTIC TARGET. AN ANALYSIS FROM THE AUSTRIAN MYELOMA REGISTRY (AMR)

PO-051 | S. Gentili | NORMALIZATION OF SERUM FREE LIGHT CHAIN RATIO AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IN MULTIPLE MYELOMA AS A MAJOR CRITERIA RESPONSE

PO-052 | P.J. Talley | RESULTS FROM FIRST PILOT CEQAS FOR MYELOMA GENETIC DIAGNOSIS

PO-053 | A. Kennard | COMPARISON OF FREELITE AND N LATEX SERUM FREE LIGHT CHAIN ASSAYS IN SUBJECTS WITH END STAGE RENAL DISEASE ON HAEMODIALYSIS

PO-054 | S. Hwang | CLONAL CHANGES ARE FREQUENTLY DETECTED BY CYTOPLASMIC IMMUNOGLOBULIN-FLUORESCENCE IN SITU HYBRIDIZATION WITH PROGRESSION OF MULTIPLE MYELOMA

PO-055 | J.J. Lee | PROGNOSTIC VALUE OF THE INVERSE PLATELET-TO-LYMPHOCYTE RATIO (IPLR) IN PATIENTS WITH MULTIPLE MYELOMA WHO WERE TREATED UPFRONT WITH A NOVEL-AGENT-CONTAINING REGIMEN

PO-056 | J.J. Lee | EARLY MORTALITY IN THE PATIENTS WITH MULTIPLE MYELOMA WHO WERE TREATED UPFRONT WITH A NOVEL-AGENT-CONTAINING REGIMEN
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO-057</td>
<td>J. Batini: Utility of the heavy/light chain assay in the evaluation of complete response to therapy in multiple myeloma patients</td>
<td>PO-073: P.P. Kotoucek: Capillary zone electrophoresis is a very sensitive method for diagnosis and monitoring of multiple clones of multiple myeloma, other plasma cell dyscrasias and lymphoproliferative disorders</td>
</tr>
<tr>
<td>PO-058</td>
<td>N. Nishimura: Multiple myeloma as a second primary malignancy; one fourth of patients had prior history of other malignancies</td>
<td>PO-074: A. Zober: Prospective assessment of comorbidity and functional geriatric assessment (CF-GA), including the revised Freiburg comorbidity index (FRCI) in MM patients (PTS)</td>
</tr>
<tr>
<td>PO-060</td>
<td>W.K. Jeong: Expiration: inspiration ratio as a prognostic factor in systemic AL amyloidosis</td>
<td>PO-076: Y. Meddour: Prognostic value of flow cytometric antigen expression pattern on bone marrow neoplastic plasma cells from multiple myeloma patients</td>
</tr>
<tr>
<td>PO-061</td>
<td>E. Lee: Baseline F-18 FDG PET uptake of bone marrow as a survival predictor in patients with multiple myeloma</td>
<td>PO-077: T. Pika: Translocation (t(8;14)) in multiple myeloma defines patients with very poor prognosis – single centre experience</td>
</tr>
<tr>
<td>PO-062</td>
<td>R. Bergner: Influence of kidney histology on prognosis in multiple myeloma</td>
<td>PO-078: S. Cerdá: IMWG '03 vs '14 diagnostic criteria for symptomatic multiple myeloma: will we have to solve a problem?</td>
</tr>
<tr>
<td>PO-063</td>
<td>M. Ikeda: The clinical significance of decreasing CD138 positive myeloma cells in bone marrow</td>
<td>PO-079: Y. Meddour: Clinical value of serum free light chain assay in Algerian newly diagnosed multiple myeloma undergoing high dose therapy</td>
</tr>
<tr>
<td>PO-064</td>
<td>I. Walker: A single centre retrospective analysis of diagnostic fluorescence in situ hybridisation reveals distinct groups of cytogenetic abnormalities, which affect early survival of new myeloma diagnosis</td>
<td>PO-080: A. Ghosh: A cytof-based approach to detect minimal residual disease in patients with multiple myeloma</td>
</tr>
<tr>
<td>PO-065</td>
<td>S.S. Yoon: Revealing genomic profile that underlies tropism of myeloma cells using whole exome sequencing</td>
<td>PO-081: N. Schütz: Frailty burden is associated with survival in elderly patients with diagnosis of multiple myeloma</td>
</tr>
<tr>
<td>PO-066</td>
<td>J. Dallemagne: Comparison of bone marrow aspirate and bone marrow biopsy in the workup of patients with multiple myeloma</td>
<td>PO-082: J.A. Kim: MYD88 L265P mutations are correlated with 6q deletion in Korean patients with Waldenström macroglobulinemia</td>
</tr>
<tr>
<td>PO-067</td>
<td>T.A. Richards: Characteristics of myeloma (MM) patients (PTS) with central nervous system (CNS) involvement</td>
<td>PO-083: O. Annibali: Alkaline phosphatase (ALP) levels in multiple myeloma (MM) and cancer with bone lesions: is there any difference?</td>
</tr>
<tr>
<td>PO-068</td>
<td>S. Hagiwara: High expression of APO1 is an adverse prognostic factor in multiple myeloma patients treated with autologous stem cell transplantation</td>
<td>PO-084: A. Jorge: Central nervous system infiltration by plasma cells: rare occurrence in multiple myeloma patients</td>
</tr>
<tr>
<td>PO-070</td>
<td>I. Jaffer Sathnick: Cast nephropathy vs acute tubular necrosis in newly diagnosed multiple myeloma: a comparative study</td>
<td>PO-086: D. Stoumbos: High serum lactate dehydrogenase level used as a prognostic factor in multiple myeloma</td>
</tr>
<tr>
<td>PO-071</td>
<td>H. Plonkova: Comparison of whole-body low-dose computed tomography and conventional radiography in the staging of multiple myeloma</td>
<td>PO-072: V. Maisnar: The significance of hevylite test for determination of prognosis in patients with asymptomatic multiple myeloma: the results of a new retrospective study</td>
</tr>
</tbody>
</table>
2 Multiple Myeloma Therapy in Newly Diagnosed Patients including Transplantation

POSTER DISCUSSION SESSION
Chairman: Andrzej J. Jakubowiak

BP-011  L. Rosiñol  PRETRANSPLANT INDUCTION WITH VTD (BORTEZOMIB/THALIDOMIDE /DEXAMETHASONE) SIGNIFICANTLY IMPROVES PFS: LONG-TERM RESULTS OF THE RANDOMIZED PHASE 3 PETHEMA/GEM STUDY

BP-012  C. Pawlyn  THE QUADRUPLE KTCD (CARFILZOMB, CYCLOPHOSPHAMIDE, LENALIDOMIDE, AND DEXAMETHASONE) IS SAFE AND WELL TOLERATED AS INDUCTION THERAPY FOR NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE, MYELOMA PATIENTS

BP-013  P. Hari  INDUCTION REGIMENS FOR AUTOLOGOUS TRANSPLANT (AHCT) ELIGIBLE MYELOMA (MM) PATIENTS (PTS) – DOUBLETOM OR TRIPLETs AND WHICH TRIPLET?

BP-014  D. Reece  MYELOMA CANADA RESEARCH NETWORK (MCRN) 001 TRIAL WITH INTRAVENOUS (IV) BUSULFAN + MELPHALAN (BUEML) AS ENHANCED CONDITIONING, FOLLOWED BY LENALIDOMIDE (LEN) MAINTENANCE IN NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS (PTS): FIRST RESULTS OF MINIMAL RESIDUAL DISEASE (MRD) AND HEMYLLITE(TM) CHAIN (HLC) ASSAYS AT DAY 100 POST AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)

BP-015  A. Kalff  IMMUNOHISTOCHEMICAL (IHC) BIOMARKERS ASSOCIATED WITH RESPONSE AND SURVIVAL FOLLOWING LENALIDOMIDE AND PREDNISOLONE MAINTENANCE POST-ASCT IN PATIENTS WITH MM: AN EXPLORATORY, HYPOTHESIS GENERATING SUB-STUDY OF THE LEOPARD TRIAL

BP-016  R. Mina  IMPACT OF COMPLETE RESPONSE ON PROGRESSION-FREE SURVIVAL AND OVERALL SURVIVAL IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH AUTOLOGOUS STEM CELL TRANSPLANTATION OR CONVENTIONAL CHEMOTHERAPY: RESULTS OF A POOLED ANALYSIS OF 5 PHASE III TRIALS

BP-017  C. Cerrato  CONTINUOUS TREATMENT IMPROVES SURVIVAL OF NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS ACHIEVING COMPLETE RESPONSE: DATA FROM 5 PHASE III TRIALS INCLUDING YOUNG AND ELDERLY PATIENTS

BP-018  K. Weisel  THE TREATMENT (TX) OF PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) INELIGIBLE FOR TRANSPLANT: A SYSTEMATIC LITERATURE REVIEW AND NETWORK META-ANALYSIS

BP-019  X. Qin  MULTIPLE MYELOMA PATIENTS WITH UNMEASURABLE DISEASE BENEFIT LESS FROM BORTEZOMIB-BASED REGIMENS

BP-020  N. Bahlis  IMPACT OF RESPONSE IN PATIENTS (PTS) WITH STEM CELL TRANSPLANT (SCT)-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) TREATED WITH CONTINUOUS LENALIDOMIDE + LOW-DOSE DEXAMETHASONE (RD) IN THE FIRST TRIAL

POSTER SESSION

PO-087  M. Mohty  FRONTLINE THERAPY FOR MULTIPLE MYELOMA (MM) IN REAL-WORLD CLINICAL PRACTICE: RESULTS FROM THE THIRD INTERIM ANALYSIS OF THE MULTINATIONAL, NON-INTERVENTIONAL, OBSERVATIONAL EMMS STUDY

PO-088  A. Jurczyszyn  CENTRAL NERVOUS SYSTEM INVOLVEMENT BY MULTIPLE MYELOMA: A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY OF 172 PATIENTS

PO-089  O. Sezer  IMPROVED TUMOR RESPONSE AND SURVIVAL OUTCOMES WITH POST-TRANSPLANT BORTEZOMIB (BTZ) CONSOLIDATION VS OBSERVATION (OBS) ALONE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (MM): RESULTS FROM A RANDOMIZED, OPEN-LABEL, MULTICENTER, PARALLEL-GROUP PHASE 2 STUDY

PO-090  C. Hulin  CONTINUOUS TREATMENT WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA IN THE FIRST TRIAL: IMPACT OF AGE

PO-091  A. Natale  IMPROVEMENT OF QUALITY OF RESPONSE AFTER ADDITIONAL THERAPY BEFORE AUTOLOGOUS STEM CELL TRANSPLANT IS NOT TRANSLATED IN IMPROVEMENT OF GLOBAL OUTCOME OF MULTIPLE MYELOMA PATIENTS

PO-092  P. Lawasut  EFFECT OF HIGH DOSE MELPHALAN ADMINISTRATION SCHEDULE: COMPARISON BETWEEN 1-DAY AND 2-DAY DOSE FOR MYELOMA CONDITIONING REGIMEN

PO-093  A. Kalff  A 2-STAGE PHASE II STUDY OF PANOBINOSTAT CONSOLIDATION IN MYELOMA PATIENTS WITH < CR FOLLOWING HIGH-DOSE CHEMOTHERAPY (HD) CONDITIONED AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)

PO-094  A. Kalff  LEOPARD: A PHASE II STUDY OF POST AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) MAINTENANCE LENALIDOMIDE AND PREDNISOLONE FOR MYELOMA (MM), INCORPORATING MINIMAL RESIDUAL DISEASE (MRD) ASSESSMENTS

PO-095  I. Ahmad  FAVORABLE LONG-TERM SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA USING A FRONTLINE TANDEM APPROACH WITH AUTOLOGOUS AND NONMYELOBLASTIC ALLOGENEIC TRANSPLANTATION

PO-096  T. Facon  UPDATED OVERALL SURVIVAL (OS) ANALYSIS OF THE FIRST STUDY: LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) CONTINUOUS VS MELPHALAN, PREDNISONE, AND THALIDOMIDE (MPT) IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

PO-097  H. Ludwig  HEAVY/LIGHT CHAIN ASSAYS IDENTIFY MONOCLONAL INTACT IMMUNOGLOBULIN IN LIGHT CHAIN ONLY PATIENTS
PO-098  A. Gazzetti  BORTEZOMIB BASED THERAPIES AND HIGH CUT OFF FILTER DIALYSIS (HCO) ARE EFFECTIVE IN MULTIPLE MYELOMA PATIENTS WITH END STAGE RENAL FAILURE

PO-099  F. De Arriba  SUBCUTANEOUS BORTEZOMIB PLUS MELPHALAN AND PREDNISONE (VMP) IN NON-TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (MM) PATIENTS: SPANISH EXPERIENCE

PO-100  T. Dejoie  SERUM FREE LIGHT CHAIN CHANGES OFFER A MORE ACCURATE ASSESSMENT OF RESPONSE TO THERAPY THAN URINE BENCE JONES PROTEIN EXCRETION MEASUREMENTS IN MULTIPLE MYELOMA

PO-101  S. Grammatico  EFFICACY OF NEW DRUGS AS TREATMENT BEFORE SINGLE OR TANDEM AUTOLOGOUS STEM CELL TRANSPLANTATION IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS

PO-102  J.J. Shah  CLINICAL OUTCOMES IN PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) AND T(4;14) IN THE CONNECT MM® REGISTRY

PO-103  R. Silvennoinen  A RANDOMIZED PHASE II STUDY OF STEM CELL MOBILIZATION WITH CYCLOPHOSPHAMIDE + G-CSF VERSUS G-CSF ALONE AFTER LENALIDOMIDE-BASED INDUCTION IN MULTIPLE MYELOMA

PO-104  N. Areethamsiri-kul  LONG-TERM CRYOPRESERVED AUTOLOGOUS BLOOD STEM CELLS FOR SALVAGE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN RELAPSED MULTIPLE MYELOMA (MM) PATIENTS

PO-105  M. Dimopoulous  CONTINUOUS LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE FOR THE TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AND RENAL IMPAIRMENT IN THE FIRST TRIAL

PO-106  N. Lendvai  RECOMBINANT MAGE-A3 PROTEIN IMMUNOTHERAPY AND PERIPHERAL BLOOD LYMPHOCYTE (PBL) RECONSTITUTION INDUCE STRONG ANTIGEN-SPECIFIC HUMORAL AND CELLULAR IMMUNE RESPONSES IN PATIENTS UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR CONSOLIDATION OF MULTIPLE MYELOMA (MM)

PO-107  J. Shin  LONG-TERM EFFICACY OF SEQUENTIAL VINCRISTINE, ADRIAMYCIN, AND DEXAMETHASONE (VAD) AND BORTEZOMIB, THALIDOMIDE, AND DEXAMETHASONE (VTD) AS INDUCTION CHEMOTHERAPY FOLLOWED BY HIGH-DOSE MELPHALAN WITH AUTOLOGOUS STEM CELL TRANSPLANTATION (AUTO-SCT) AND BORTEZOMIB CONSOLIDATION: A FOLLOW-UP STUDY OF KMM51

PO-108  C. Layayanni  IMPACT OF ANTI-MYELOMA INDUCTION TREATMENT AND OTHER PREDICTIVE FACTORS ON STEM CELL HARVESTING, IN THE NOVEL AGENT ERA

PO-109  V.H. Jimenez Zepeeda  CYCLOPHOSPHAMIDE, BORTEZOMIB, AND DEXAMETHASONE (CYBORD) INDUCTION: IMPACT ON RESPONSE RATE AND MDR NEFICITY FOR PATIENTS WITH MULTIPLE MYELOMA UNDERGOING UPFRONT VCD INDUCTION IN MULTIPLE MYELOMA: IS G-CSF ALONE SUFFICIENT?

PO-110  G. Somlo  TOTAL MARROW IRRADIATION (TMI) WITH HELICAL TOMOTHERAPY AND PERIPHERAL BLOOD PROGENITOR CELL RESCUE (PBPC) FOLLOWING HIGH-DOSE MELPHALAN (MEI) AND PBPC AS PART OF TANDEM AUTOLOGOUS TRANSPLANT (TAT) FOR PATIENTS WITH MULTIPLE MYELOMA

PO-111  J.R. Eveillard  APPRAISAL OF IGM KAPPA/IGM LAMBDA VARIATIONS USING HEVLITHE® AFTER RITUXIMAB AS CONSOLIDATION THERAPY IN PATIENTS WITH WALDENSTROM’S MACROGLOBULINEMIA

PO-112  K.T. Andersen  SAFETY AND EFFICACY OF FIRST-LINE TREATMENT WITH DOXORUBICIN, CYCLOPHOSPHAMIDE, BORTEZOMIB, DEXA-METHASONE AND LENALIDOMIDE (ACVDL) IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS OF ALL AGES

PO-113  V. Kukreti  OUTCOME OF T(4;14) IN MULTIPLE MYELOMA – PRINCESS MARGARET CANCER CENTRE EXPERIENCE OVER THE LAST 10 YEARS

PO-114  L. Kumar  AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) FOR MULTIPLE MYELOMA (MM): PREDICTORS OF LONG TERM OUTCOME

PO-115  L. Kumar  LOW DOSE DEXAMETHASONE PLUS LENALIDOMIDE (LEN-DEXA) VERSUS THALIDOMIDE (THAL-DEXA) AS INDUCTION THERAPY FOR NEWLY DIAGNOSED MULTIPLE MYELOMA: A PHASE III, RANDOMIZED STUDY

PO-116  B. Gamberi  LENALIDOMIDE MAINTENANCE CAUSES PERSISTENCE OF ABNORMAL PROTEIN BANDS IN MULTIPLE MYELOMA PATIENTS AFTER INDUCTION WITH NEW DRUGS AND AUTOLOGOUS BONE MARROW TRANSPLANTATION

PO-117  S. Cerdá  AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) OVER 65 YEARS

PO-118  A. Roque  EARLY CLINICAL OUTCOMES AND LONG-TERM SURVIVAL IN MM PATIENTS UNDERGOING AUTOLOGOUS HSCT AFTER MELPHALAN 200 MG/M2 CONDITIONING WITHOUT WEIGHT-BASED DOSE-ADJUSTMENT ARE UNAFFECTED BY BODY MASS INDEX

PO-119  V.H. Jimenez Zepeeda  PROGNOSTIC FACTORS FOR OVERALL AND PROGRESSION-FREE SURVIVAL IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING SINGLE AUTO-SCT

PO-120  M. Merz  OUTCOME AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION FOR MYELOMA IN PATIENTS BEYOND 60, 65 AND 70 YEARS OF AGE: A RETROSPECTIVE ANALYSIS FROM THE GERMAN REGISTRY FOR STEM CELL TRANSPLANTATION (DRST)

PO-121  C.C. Chua  A MULTI-CENTRE REVIEW OF MOBILISATION STRATEGIES POST UPFRONT VCD INDUCTION IN MULTIPLE MYELOMA: IS G-CSF ALONE SUFFICIENT?
<table>
<thead>
<tr>
<th>ID</th>
<th>Title</th>
<th>Authors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO-122</td>
<td>SKIN INVOLVEMENT BY MULTIPLE MYELOMA: A MULTI-INSTITUTIONAL RETROSPECTIVE STUDY OF 53 PATIENTS</td>
<td>A. Jurczyszyn</td>
</tr>
<tr>
<td>PO-123</td>
<td>A RESPONSE ADAPTATED APPROACH TO INDUCTION TREATMENT YIELDS ACCEPTABLE OUTCOME IN PATIENTS WITH MULTIPLE MYELOMA (MM) UNDERGOING AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT)</td>
<td>G.L. Shah</td>
</tr>
<tr>
<td>PO-124</td>
<td>VCD, VD AND VMP IN FRONT LINE TREATMENT: OUTCOMES FROM THAI MYELOMA WORKING GROUP – PATIENT ASSISTANCE PROGRAM (TMWG-PAP)</td>
<td>P. Lawasut</td>
</tr>
<tr>
<td>PO-125</td>
<td>NUMBER OF CD34+ CELLS COLLECTED BETWEEN TWO DIFFERENT MOBILIZATION SCHEDULES IN MULTIPLE MYELOMA PATIENTS WITH CTD INDUCTION AND CANDIDATES FOR AUTOLOGOUS TRANSPLANT OF HEMATOPOIETIC PROGENITOR CELLS</td>
<td>E. de Queiroz Crusoе</td>
</tr>
<tr>
<td>PO-126</td>
<td>PROGRESSION-FREE SURVIVAL FOLLOWING AUTOLOGOUS TRANSPLANTATION FOR MULTIPLE MYELOMA IS NOT COMPROMISED BY THE USE OF DOSE-ADJUSTED MELPHALAN</td>
<td>J. Sangha</td>
</tr>
<tr>
<td>PO-127</td>
<td>SUCCESSFUL ASSESSMENT AND EDUCATIONAL INTERVENTION OF GUIDELINE-BASED APPROACHES FOR THE MANAGEMENT OF MULTIPLE MYELOMA</td>
<td>E.S. Van Laar</td>
</tr>
<tr>
<td>PO-128</td>
<td>THE EFFICACY AND SAFETY OF HIGH DOSE MELPHARAN PLUS BORTEZOMIB FOLLOWED BY AUTO PBSCT IN ELDERLY MULTIPLE MYELOMA PATIENTS</td>
<td>N. Takezako</td>
</tr>
<tr>
<td>PO-129</td>
<td>COMPARISON OF THE PERFORMANCE OF THE NEWLY DEVELOPED IGA HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUM PROTEIN ELECTROPHORESIS AND NEPHELOMETRIC TOTAL IGA MEASUREMENTS FOR MONITORING IGA MULTIPLE MYELOMA PATIENTS</td>
<td>O. Berlanga</td>
</tr>
<tr>
<td>PO-130</td>
<td>PRE TRANSPLANT ACHIEVEMENT OF VERY GOOD PARTIAL RESPONSE RESULTS IN IMPROVED SURVIVAL IN MYELOMA</td>
<td>O.S. Yeu</td>
</tr>
<tr>
<td>PO-131</td>
<td>EARLY PROGRESSION (WITHIN 12 MONTHS) AFTER AUTOLOGOUS STEM-CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA</td>
<td>S.H. Lim</td>
</tr>
<tr>
<td>PO-132</td>
<td>CLINICAL FEATURES AND OUTCOMES AFTER AUTO-SCT IN PATIENTS WITH MULTIPLE MYELOMA AND RENAL IMPAIRMENT</td>
<td>H. Ryu</td>
</tr>
<tr>
<td>PO-133</td>
<td>STEM CELL MOBILIZATION AND AUTOLOGOUS STEM CELL TRANSPLANTATION AFTER PRETREATMENT CONSISTING OF BENZAMUSTINE, PREDNISONE AND BORTEZOMIB (BPV) IN 35 PATIENTS WITH NEWLY DIAGNOSED/UNTREATED MULTIPLE MYELOMA</td>
<td>W. Poenisch</td>
</tr>
<tr>
<td>PO-134</td>
<td>SERUM FREE LIGHT CHAIN ASSAYS, NOT TOTAL LIGHT CHAIN ASSAYS, ARE THE STANDARD OF CARE IN THE ASSESSMENT OF MONOCLONAL GAMMOPATHIES</td>
<td>V. Hungria</td>
</tr>
<tr>
<td>PO-135</td>
<td>HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS FOR MONITORING</td>
<td>O. Berlanga</td>
</tr>
<tr>
<td>PO-136</td>
<td>THE TREATMENT STRATEGIES IN PATIENTS WITH PARTIAL RESPONSE TO HIGH-DOSE CHEMOTHERAPY AND ASCT</td>
<td>S.K. Park</td>
</tr>
<tr>
<td>PO-137</td>
<td>ENGRAFTMENT SYNDROME DURING AUTO HSCT IN PLASMA CELL DISORDERS: RETROSPECTIVE ANALYSIS OF CONSECUTIVE CASES FROM A TERTIARY CARE CENTRE</td>
<td>R. Pramanik</td>
</tr>
<tr>
<td>PO-138</td>
<td>RETROSPECTIVE ANALYSIS OF THE IMPACT OF KIDNEY FUNCTION ON THE OUTCOMES OF FIRST AUTOGRFTS FOR DE NOVO MYELOMA PATIENTS IN THE ERA OF NOVELAGENTS</td>
<td>L. Fioro</td>
</tr>
<tr>
<td>PO-139</td>
<td>COMPARISON OF THE PERFORMANCE OF THE NEWLY DEVELOPED IGG HEAVY CHAIN/LIGHT CHAIN IMMUNOASSAYS WITH SERUM PROTEIN ELECTROPHORESIS FOR MONITORING IGG MULTIPLE MYELOMA PATIENTS</td>
<td>O. Berlanga</td>
</tr>
<tr>
<td>PO-140</td>
<td>IDENTIFICATION OF PREDICTOR FACTORS FOR EARLY RELAPSE (ER) IN PATIENTS WITH MM UNDERGOING SINGLE AUTO-SCT</td>
<td>V.H. Jimenez Zepeda</td>
</tr>
<tr>
<td>PO-141</td>
<td>PHASE 1 STUDY OF ELOTUZUMAB (ELO) IN COMBINATION WITH LENALDIDMIDE/DEXAMETHASONE (LEN/DEX) IN JAPANESE PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RMM) AND LONG-TERM FOLLOW-UP</td>
<td>T. Chou</td>
</tr>
<tr>
<td>PO-142</td>
<td>SUBCUTANEOUS ADMINISTRATION OF BORTEZOMIB SIGNIFICANTLY DECREASED AND DELAYED THE DEVELOPMENT OF PERIPHERAL NEUROPATHY IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA</td>
<td>Y. Xu</td>
</tr>
<tr>
<td>PO-143</td>
<td>MELPHALAN 140MG/M2* SIGNIFICANTLY REDUCES 5 YEAR PROGRESSION FREE SURVIVAL IN MULTIPLE MYELOMA PATIENTS RECEIVING A PERIPHERAL BLOOD AUTOLOGOUS STEM CELL TRANSPLANT COMPARED WITH MELPHALAN 200MG/M2*</td>
<td>C. Attwood</td>
</tr>
<tr>
<td>PO-144</td>
<td>REGISTRY BASED RETROSPECTIVE ANALYSIS OF BENZAMUSTINE CONDITIONED SECOND AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTS FOR RELAPSED MYELOMA</td>
<td>L. Fioro</td>
</tr>
<tr>
<td>PO-145</td>
<td>THE EMPEROR IS NAKED: THE QUALITY OF RESPONSE TO FIRST-LINE THERAPY IS NOT RELATED TO SURVIVAL IN MULTIPLE MYELOMA (MM) PATIENTS</td>
<td>I. Hardan</td>
</tr>
<tr>
<td>PO-146</td>
<td>PHASE 2 STUDY USING INTRAVENOUS BUSULFAN AND MELPHALAN CONDITIONING REGIMEN FOR AUTOLOGOUS STEM CELL TRANSPLANTATION IN PATIENTS WITH MULTIPLE MYELOMA: INTERIM ANALYSIS (KMM150)</td>
<td>J.J. Lee</td>
</tr>
<tr>
<td>PO-147</td>
<td>INCREASED INCIDENCE OF SYMPTOMATIC POSTURAL HYPTENSION IN MULTIPLE MYELOMA PATIENTS TREATED WITH SUBCUTANEOUS BORTEZOMIB</td>
<td>S. Ahmed</td>
</tr>
<tr>
<td>PO-148</td>
<td>HEALTH RESOURCE UTILIZATION WITH CONTINUOUS LENALDIDMIDE TREATMENT (TX) IN ELDERLY PATIENTS (PTS) WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)</td>
<td>K. Weisel</td>
</tr>
<tr>
<td>POSTER SESSION</td>
<td>TITLE</td>
<td>AUTHOR(S)</td>
</tr>
<tr>
<td>-----------------------------</td>
<td>----------------------------------------------------------------------</td>
<td>--------------------------------</td>
</tr>
<tr>
<td>PO-149</td>
<td>SUCCESSFUL STEM CELL COLLECTION IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS OVER 65 YEARS OLD</td>
<td>C. Cecchini</td>
</tr>
<tr>
<td>PO-150</td>
<td>AUTOLOGOUS STEM CELL COLLECTION AFTER BIOSIMILAR G-CSF (ZARZIO® COMPARED TO ORIGINAL G-CSF (NEUPOGEN®) IN MULTIPLE MYELOMA PATIENTS</td>
<td>J. Radocha</td>
</tr>
<tr>
<td>PO-151</td>
<td>SUCCESSFUL TREATMENT OF PATIENTS WITH NEWLY DIAGNOSED/UNTREATED LIGHT CHAIN MULTIPLE MYELOMA WITH A COMBINATION OF BENDAMUSTINE; PREDNISONE AND BORTEZOMIB (BPV)</td>
<td>H. Mrachacz</td>
</tr>
<tr>
<td>PO-152</td>
<td>COMPARISON OF THE CLINICAL SENSITIVITY OF TWO FREE LIGHT CHAIN ASSAYS IN A COHORT OF LIGHT CHAIN MULTIPLE MYELOMA PATIENTS</td>
<td>T. Dejoie</td>
</tr>
<tr>
<td>PO-153</td>
<td>FRONTLINE TREATMENT SCHEME VTD (BORTEZOMIB/THALIDOMIDE/DEXAMETHASONE) IN PATIENTS WITH MULTIPLE MYELOMA TRANSPLANT CANDIDATES AT OUR CENTER</td>
<td>R. Garcia Sanchez</td>
</tr>
<tr>
<td>PO-154</td>
<td>AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AL AMYLOIDOSIS</td>
<td>H.N. Song</td>
</tr>
<tr>
<td>PO-155</td>
<td>DAY 4 PERIPHERAL BLOOD STEM CELL COLLECTION IN MYELOMA PATIENTS IS FEASIBLE AND AND COST-EFFECTIVE IN A MAJORITY OF PATIENTS</td>
<td>E. Kaul</td>
</tr>
<tr>
<td>PO-156</td>
<td>EVALUATION OF THE NOVEL HEVLYTILE® IGK KAPPA/IGM LAMBDA ASSAYS IN WALDENSTRÖM'S MACROGLOBULINEMIA PATIENTS AFTER RITUXIMAB CONSOLIDATION THERAPY</td>
<td>J.R. Eveillard</td>
</tr>
<tr>
<td>PO-157</td>
<td>THE EVOLVING ROLE OF STEM CELL TRANSPLANT IN MULTIPLE MYELOMA: A SINGLE INSTITUTION STUDY</td>
<td>R. Rios-Tamayo</td>
</tr>
<tr>
<td>PO-158</td>
<td>PREDICTION OF POOR MOBILIZATION OF PERIPHERAL BLOOD STEM CELLS (PBSC) WITH G-CSF ALONE, IN MULTIPLE MYELOMA (MM) PATIENTS UNDERGOING AUTOLOGOUS TRANSPLANTATION: A PROSPECTIVE STUDY</td>
<td>R.R. Boya</td>
</tr>
<tr>
<td>PO-159</td>
<td>STEM CELL TRANSPLANTATION FOR MULTIPLE MYELOMA: SINGLE CENTER EXPERIENCE</td>
<td>Z. Bolaman</td>
</tr>
<tr>
<td>PO-160</td>
<td>BORTEZOMIB BASED REGIMEN IN YOUNG HIGH RISK MULTIPLE MYELOMA PATIENTS RELAPSED AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: TWO CLINICAL CASES</td>
<td>M. Quaresima</td>
</tr>
<tr>
<td>PO-161</td>
<td>AUTOLOGOUS STEM CELL TRANSPLANTATION AND PRIMARY SYSTEMIC LIGHT CHAIN (AL) AMYLOIDOSIS</td>
<td>S.K. Toprak</td>
</tr>
<tr>
<td>PO-162</td>
<td>FOUR PHASE 3 STUDIES OF THE ORAL PROTEASOME INHIBITOR (PI) IXAZOMIB FOR MULTIPLE MYELOMA IN THE NEWLY-DIAGNOSED, RELAPSED/REFRACTORY, AND MAINTENANCE SETTINGS: TURMALINE-MM1, -MM2, -MM3, AND -MM4</td>
<td>J. San Miguel</td>
</tr>
<tr>
<td>ID</td>
<td>Title</td>
<td>Authors</td>
</tr>
<tr>
<td>------</td>
<td>----------------------------------------------------------------------</td>
<td>------------------------------------------------------------------------</td>
</tr>
</tbody>
</table>
PO-199 R. Kaedbey A RETROSPECTIVE ANALYSIS AT THE PRINCESS MARGARET CANCER CENTRE OF THE INITIAL THERAPY OF ALAMYLOIDOSIS: CYBORD VERSUS OTHER REGIMENS

PO-200 C.K. Min TREATMENT RESULTS OF VENOUS THROMBOEMBOLISM WITH DALTEPARIN IN PATIENTS WITH MULTIPLE MYELOMA UNDERGOING ANTI-MYELOMA CHEMOTHERAPEUTIC AGENTS

PO-201 R. Ria SUBCUTANEOUS IMMUNOGLOBULIN FOR TREATMENT OF SECONDARY HYPOGAMMAGLOBULINEMIA IN MULTIPLE MYELOMA

PO-202 R. Pramanik POEMS SYNDROME: A RETROSPECTIVE ANALYSIS OF CLINICO-PATHOLOGICAL PROFILE AND TREATMENT OUTCOMES OF 43 CONSECUTIVE CASES FROM A TERTIARY CANCER CENTRE IN INDIA

PO-203 J. Page FOLLOWING THE GUIDELINES FOR REDUCING OSTEONECROSIS OF THE JAW ASSOCIATED WITH BISPHOSPHONATE THERAPY IN SYMPTOMATIC MULTIPLE MYELOMA: EXPERIENCE OF A DISTRICT GENERAL HOSPITAL

PO-204 C. Vadikoliou SECONDARY MALIGNANCIES IN MULTIPLE MYELOMA

PO-205 E. Sahovic AUTOLOGOUS HCT IN ELDERLY MYELOMA PATIENTS, AHNCI SINGLE INSTITUTION EXPERIENCE

PO-206 S. Mahmood BLEEDING DIATHESIS AND PROTHROMBOTIC TENDENCIES IN PATIENTS WITH NEWLY DIAGNOSED SYSTEMIC LIGHT CHAIN AMYLOIDOSIS: IMPORTANT CLINICAL IMPLICATIONS

PO-207 V. Maisnar CZECH MYELOMA GROUP REGISTRY OF MONOCLONAL GAM- MOPATHIES

PO-208 F. Almagro Torres PLASMA CELL LEUKEMIA. EXPERIENCE IN OUR CENTER

PO-209 O.G. Sevindik QUALITY OF LIFE IN MULTIPLE MYELOMA: VALIDATION OF THE TURKISH VERSION OF THE QLQ-MY20 INSTRUMENT

PO-210 Y. Yoshiki THE VERIFICATION OF RENAL PROGNOSIS OF ALAMYLOIDOSIS

PO-211 P.P. Kotoucek FINDING THE MEANING OF LIFE OF PATIENTS WITH MULTIPLE MYELOMA CORRELATES WITH BETTER CONTROL OF THEIR DISEASE BY CHEMOTHERAPY

PO-212 A. Vicent Castelló INCIDENCE OF NEUROPATHY IN PATIENTS TREATED WITH BORTEZOMIB SUBCUTANEOUS

PO-213 A. Alegre MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE (MGRS), HEMATOLOGICAL AND RENAL COMPLETE RESPONSE WITH BORTEZOMIB

PO-214 F. Escalante SAFETY AND ADHESION WITH SUBCUTANEOUS BORTEZOMIB TREATMENT IN MULTIPLE MYELOMA

PO-215 A. García-Guiñón INCIDENCE OF PERIPHERAL NEUROPATHY IN CLINICAL PRACTICE IN MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB REGIMENS
4. Multiple Myeloma Biology, Pathophysiology, Preclinical Studies, Bone Disease

POSTER DISCUSSION SESSION
Chairman: Noopur Raye

BP-031  E. Dhimolea
FUNCTIONAL MAPPING OF MULTIPLE MYELOMA KINOME WITH LIBRARY OF SMALL MOLECULE INHIBITORS

BP-032  Y.X. Zhu
IDENTIFICATION OF FAM46C AS A TUMOR SUPPRESSOR IN MULTIPLE MYELOMA

BP-033  S. Parekh
TARGETING MYC VIA ARK5 IN MULTIPLE MYELOMA

BP-034  S. Janz
ADOPTIVE B-CELL TRANSFER MOUSE MODEL OF HUMAN MYELOMA

BP-035  H. Suen
CYTOTOXIC CD8+ T CELLS IN MYELOMA ARE IN A STATE OF TELOMERE-INDEPENDENT SENESCENCE RATHER THAN AN EXHAUSTED OR ANERGIC STATE: IMPLICATION FOR IMMUNE CHECKPOINT BLOCKADE

BP-036  T. Gogishvili
ANTI-MYELOMA ACTIVITY OF CS-1-SPECIFIC CHIMERIC ANTIGEN RECEPTOR (CAR) EXPRESSING T CELLS IN VITRO AND IN PRE-CLINICAL IN VIVO MODELS

BP-037  E. Viziteu
ROLE OF RECQ1 HELICASE IN MULTIPLE MYELOMA DRUG RESISTANCE

BP-038  T. Perini
A PLASTIC SQSTM1/P62-DEPENDENT AUTOPHAGIC RESERVE MAINTAINS PROTEIN HOMEOSTASIS AND DETERMINES PROTEASOME INHIBITOR SUSCEPTIBILITY IN MULTIPLE MYELOMA CELLS

BP-039  A. Reale
TOP2A KNOCKDOWN RESENSITIZES CARFILZOMIB-RESISTANT HMCLs TO CARFILZOMIB

BP-040  P. Neri
IMIDS INDUCED Ikaros-dependent downregulation of MYC in MYELOMA IS MEDIATED THROUGH THE REPRESSION OF THE 3' IGH ENHANCER ACTIVITY AND THE NURD COMPLEX REPOSITIONING

POSTER SESSION

PO-224  C. Giallongo
GRANULOCYTE-LIKE MYELOID DERIVED SUPPRESSOR CELLS (G-MDSCS) ARE INCREASED IN MULTIPLE MYELOMA DUE TO IMMUNOLOGICAL DYSREGULATION OF MESENCHYMAL STEM CELLS (MSCs)

PO-225  I. Savvidou
TARGETING THE WNT CANONICAL PATHWAY IN MULTIPLE MYELOMA (MM) WITH BC2059, A NEW ORALLY BIOAVAILABLE B-CATENIN INHIBITOR

PO-226  T. Khong
TRAMETINIB COMBINED WITH DEXAMETHASONE INDUCES BIM-DEPENDENT SYNERGISTIC KILLING OF PREVIOUSLY DEXAMETHASONE REFRACTORY MYELOMA

PO-227  V.C. Ramani
TARGETING HEPARANASE TO INHIBIT MYELOMA CHEMORESISTANCE

PO-228  C. Pawlyn
EZH2 OVEREXPRESSION IN MYELOMA PATIENTS SHORTENS SURVIVAL AND IN-VITRO DATA SUPPORTS A POTENTIAL NEW TARGETED TREATMENT STRATEGY

PO-229  S. Hernández-Garcia
FILANESIB (ARRY-520) DEMONSTRATES POTENT AND RAPID ACTIVITY IN PRECLINICAL MODELS OF MM, DEPENDENT ON BCL-2 FAMILY EXPRESSION, AND SYNERGISTIC WITH DEXAMETHASONE AND IMIDS

PO-230  M. Ishibashi
REVERSE SIGNALING VIA B7-H1/PD-1 INTERACTION AND CLINICAL CHARACTERISTICS OF B7-H1 (PD-L1) EXPRESSED ON MULTIPLE MYELOMA CELLS

PO-231  J. Devin
INHIBITION OF H3K9 METHYLTRANSFERASE AS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA

PO-232  F. Fan
THE AP-1 TRANSCRIPTION FACTOR JUNB PROMOTES MULTIPLE MYELOMA (MM) CELL PROLIFERATION, SURVIVAL AND DRUG RESISTANCE IN THE BONE MARROW MICROENVIRONMENT

PO-233  D. Quwaider
A NOVEL FUNCTION OF DEPTOR IN MULTIPLE MYELOMA: COMMITMENT TO PLASMA CELL MATURATION

PO-234  Y. Qin
MIR-137 CONTRIBUTES TO DRUG SUSCEPTIBILITY AND CHROMOSOMAL INSTABILITY OF MULTIPLE MYELOMA THROUGH TARGETING AURKA

PO-235  M. Zangari
SURGICAL CONTROL/CURE OF STG11 MURINE MULTIPLE MYELOMA MODEL BY THYROPARATHYROIDECTOMY

PO-236  Z. Xie
MMSET I ACTS AS AN ONCOGENE IN T(4;14) MULTIPLE MYELOMA CELLS

PO-237  H. Miki
EFFECTIVE IMPAIRMENT OF MYELOMA PROGENITORS BY HYPERTHERMIA: AUGMENTATION WITH BORTEZOMIB AND PIM INHIBITION IN COMBINATION

PO-238  A.A. López-Iglesias
PRECLINICAL ANTIMYELOMA ACTIVITY OF EDO-S101

PO-239  M.C. Rapanotti
BONE MARROW ANGIogenic POTENTIAL AND MOLECULAR EXPRESSION OF CELL-CELL ADHESION MOLECULES AND MATRIX-METALLO PROTEINASES IN MULTIPLE MYELOMA

PO-240  S. Yousef
CANCER-TESTIS ANTIGEN SLP111 REPRESENTS A PROMISING TARGET FOR THE IMMUNOTHERAPY OF MULTIPLE MYELOMA

PO-241  P. Abdollahi
PRL-3 INCREASES SURVIVAL OF MULTIPLE MYELOMA CELLS THROUGH SRC ACTIVATION

PO-242  K. Klausz
A NOVEL HUMAN FC-OPTIMIZED ICAM-1/CD54 ANTIBODY (MSH-15E) WITH POTENT ANTI-MYELOMA ACTIVITY IN VITRO AND IN Vivo
15 INTERNATIONAL MYELOMA WORKSHOP
Auditorium Parco della Musica

**Targeting of BMI-1 by the small molecule inhibitor PTC-209 demonstrates potent anti-myeloma activity in vitro**

**GDF15 promotes osteoclast differentiation and high serum GDF15 levels are associated with multiple myeloma bone disease**

**Targeting metabolism in multiple myeloma enhances BIM binding to BCL-2 eliciting synthetic lethality to ABT-199**

**GRP78 (78-kDa glucose-regulated protein) is a potentially useful biomarker for predicting response and survival outcome in patients with multiple myeloma, and is a potentially useful target in the treatment of multiple myeloma**

**Bortezomib and CARFILZOMIB-resistant multiple myeloma cells generated in vitro match the molecular hallmarks of bortezomib-resistant primary myeloma cells, but differ in their sensitivity to bortezomib, CARFILZOMIB and novel proteasome-inhibiting drugs**

**Identification of FAM46C as a tumor suppressor in multiple myeloma**

**The novel Pan-Pim kinase inhibitor, LGH447, shows dual antitumoral and bone antiresorptive effect in multiple myeloma and synergizes with standard-of-care treatments**

**Histone deacetylase 11 (HDAC11) is critical for plasma cell development and multiple myeloma survival**

**Multiple myeloma (MM) patients in long term complete remission (LTCR) after autologous transplantation express a distinctive immune “footprint”. A single centre experience**

**High levels of periostin in patients with multiple myeloma correlate with low bone formation, increased fracture rate and diffuse MRI pattern**

**A novel 3D high-throughput coculture platform for multiple myeloma ex-vivo sensitivity testing and drug screening**

**Multiple myeloma drug resistance: All roads lead to KLF9**

**Osteoprotegerin is a significant prognostic factor for overall survival in patients with primary systemic amyloidosis independent of the Mayo staging**

**The KCA2.3 potassium channel at 1Q21 is associated with disease progression and reduced survival during relapse in multiple myeloma**

**In vivo fluorescent imaging of multiple myeloma in transplanted xenograft model**

**Characterization of TCR repertoire of CD4+ and CD8+ T cells from patients with multiple myeloma in sustained complete remission**

**RASSF4 functions as a tumor suppressor in multiple myeloma**

**Notch signaling drives myeloma cells homing to the bone marrow by regulating the CXCR4/CXCL12 axis**

**Identifying disease progression events in multiple myeloma**

**Sclerostin remains elevated even in the plateau phase of myeloma patients: Implications into the pathogenesis of osteoblast dysfunction of multiple myeloma**

**BET bromodomain blockade enhances karosinhibition by lenalidomide therapy providing additional activity in in**

**CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant myeloma cells**

**STK405759 as a novel drug for multiple myeloma therapy**

**Frequency of protease activated receptor1 (PAR1) expression and the in vitro effects of X5T and X5Z, two novel PAR1 binding molecules, on primary and Bortezomib refractory myeloma cell lines**

**Co-inhibitory molecule VSG14 negatively regulates helper T cell-dependent isotype switching and antibody response**

**Bortezomib inhibits osteoclastogenesis and bone resorption through modulation of CHIT1 and YKL40 expression**

**Survivin suppressant YM155 induces cell death via proapoptotic degradation of C-MYC in multiple myeloma cells**

**CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant myeloma cells**
PO-274  A. Bolomsky  THE CHEMOKINE CXCL9 (MIG) IS AN INDEPENDENT PREDICTOR OF OVERALL SURVIVAL IN NEWLY DIAGNOSED MULTIPLE MYELOMA

PO-275  K.M. Mrozik  N-CADHERIN IS A THERAPEUTIC TARGET IN T(4;14)-POSITIVE MULTIPLE MYELOMA

PO-276  S. Thangavadiel  MYELOMA-DERIVED CCL27 INDUCES StromA-Dependent RESISTANCE AGAINST BORTEZOMIB VIA UPREGULATION OF IL-10

PO-277  L. Zhang  POTENTIAL ROLE OF EXOSOME-ASSOCIATED MICRORNAs PANELS AND IN VIVO ENVIRONMENT TO PREDICT DRUG RESISTANCE FOR PATIENTS WITH MULTIPLE MYELOMA IN THE ERA OF NOVEL AGENTS: A RETROSPECTIVE ANALYSIS OF REAL-WORLD DATA FROM A CHINESE CENTER OF HEMATOLOGICAL DISEASE

PO-278  I. Saltarella  INVOLVEMENT OF NOTCH SIGNALING IN MULTIPLE MYELOMA ANGIogenesis AND PROGRESSION

PO-279  A. Lamanuzzi  INHIBITION OF MTor AS ANTIANGIOGENIC STRATEGY IN MULTIPLE MYELOMA

PO-280  J. Minarik  CORRELATION OF THE PARAMETERS OF MYELOMA BONE DISEASE SIGNALLING TO THE ACTIVITY OF MULTIPLE MYELOMA AND TO THE RISK OF TRANSFORMATION IN MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

PO-281  D. Tibullo  ROLE OF NUCLEAR HEME OXYGENASE 1 (HO-1) IN BORTEZOMIB INDUCED CELL DEATH AND GENOMIC INSTABILITY OF MULTIPLE MYELOMA (MM) CELLS

PO-282  L.J. Crawford  HUWE1 IS A POTENTIAL THERAPEUTIC TARGET IN MULTIPLE MYELOMA

PO-283  A. Yamada  EXPRESSION AND FUNCTION OF SLAM FAMILY MOLECULE SLAMF3 (CD229) IN MYELOMA

PO-284  M. G kotzamani dou  DEFICIENCY IN DNA REPAIR PATHWAYS OF PERIPHERAL BLOOD MONONUCLEAR CELLS CORRELATES WITH BETTER CLINICAL OUTCOME OF MYELOMA PATIENTS

PO-285  N. Shingen  ALTERATION OF PIM-2 EXPRESSION BY CLINICALLY AVAILABLE ANTI-MYELOMA AGENTS: COMBINATORY ANTI-MYELOMA EFFECTS WITH PIM INHIBITION

PO-286  E. Grywalska  RELATION BETWEEN LYMPHOCYTES AND DENDRITIC CELLS - IMPLICATIONS FOR THE EFFECTIVENESS OF AN IMMUNE RESPONSE TO NEOPLASTIC ANTIGENS IN PATIENTS SUFFERING FROM MULTIPLE MYELOMA

PO-287  X. Qu  THE MECHANISMS AND EFFECTS OF LONG NONCODING RNA MATERIALLY EXPRESSED 3 IN MULTIPLE MYELOMA

PO-288  P.G. Richardson  THE CURRENT UNMET MEDICAL NEEDS IN THE TREATMENT AND MANAGEMENT OF MULTIPLE MYELOMA (MM)

PO-289  S. Shah  CHARACTERIZATION OF HEAT SHOCK FACTOR 1 IN RESPONSE TO PROTEASOME INHIBITION UNVEILS A NOVEL THERAPEUTIC STRATEGY FOR MULTIPLE MYELOMA TREATMENT

PO-290  E. Fujii  BUFALIN INDUCES APOPTOSIS IN MYELOMA CELLS THROUGH DNA DAMAGE AT HYPOXIC CONDITIONS

PO-291  A. Leivas  AUTOLOGOUS ACTIVATED AND EXPANDED NATURAL KILLER CELLS DESTROY MULTIPLE MYELOMA CLONOCOGENIC TUMOR CELLS THROUGH NKG2D AND ITS LIGANDS

PO-292  S. Morita  CLINICOPATHOLOGICAL ANALYSIS OF MULTIPLE MYELOMA WITH CENTRAL NERVOUS SYSTEM INVOLVEMENT

PO-293  F. Costa  LENALIDOMIDE INCREASES HUMAN DENDRITIC CELL MATURATION MODULATING BOTH MONOCYTE DIFFERENTIATION AND MESENCHYMAL STROMAL CELL INHIBITORY PROPERTIES BY IKAROS DEPENDENT AND INDEPENDENT MECHANISMS

PO-294  O. Decaux  COMPARISON OF POLYCLONAL AND MONOCLONAL ANTIBODY BASED FREE LIGHT CHAIN ASSAYS TAKING ACCOUNT OF RENAL FUNCTION

PO-295  G.N. Le  STRUCTURAL CHARACTERISATION OF IMMUNOGLOBULIN G GLYCOSYLATION IN MULTIPLE MYELOMA

PO-296  H. Park  C-MET ASSOCIATED WITH OSTEOGENESIS IN MULTIPLE MYELOMA PATIENTS BY INDUCTION OF MMP9 EXPRESSION BY HGF IN BMSCS

PO-297  A. Jungbluth  EXPRESSION OF CANCER TESTIS ANTIGENS (CTAS) IN PLASMACYTOMA WITH AND WITHOUT BONE MARROW INVOLVEMENT

PO-298  M. Hao  INCREASED DN73 PROMOTES MYELOMA CELL GROWTH AND REPRESSIONS DNA DAMAGE-INDUCED APOPTOSIS

PO-299  X. Qin  CLONAL EVOLUTIONAL PATHS IN MULTIPLE MYELOMA REVEALED IN SINGLE CELL OF SEQUENTIAL ANALYSIS AND ITS CLINICAL SIGNIFICANCE

PO-300  C.K. Min  IMPACT OF LENALIDOMIDE AND DEXAMETHASONE TREATMENT ON IMMUNE CELL POPULATIONS OF THE PATIENTS WITH REFRACtORY/RELAPSED MULTIPLE MYELOMA

PO-301  Y. Jian  TARGET AND RESISTANCE RELATED PROTEINS OF RECOMBINATE MUTANT HUMAN TUMOR NECROSIS FACTOR-RELATED APOPTOSIS-INDUCING LIGAND (RMT1RAIL) ON MYELOMA CELL LINES

PO-302  E. Rojas  AMILOIDE INDUCES POTENT ANTIUMORAL ACTIVITY IN MULTIPLE MYELOMA THROUGH THE REACTIVATION OF MUTANT P53

PO-303  M. Zang  CDC37 SUPPRESSING IN MULTIPLE MYELOMA BLOCKS PROLIFERATION BUT INDUCES BORTEZOMIB RESISTANCE

PO-304  S. Jasrotia  SERUM CYTOKINE LEVELS IN PATIENTS OF MULTIPLE MYELOMA AT DIAGNOSIS AND AT RELAPSE
LENALIDOMIDE-DEXAMETHASONE OR MELPHALAN-LENALIDOMIDE-PREDNISONE (MPR) OR CYCLOPHOSPHAMIDE-PREDNISONE-LENALIDOMIDE (CPR) AS FIRST-LINE TREATMENT OF PATIENTS WITH MULTIPLE MYELOMA: RESULTS OF A RANDOMIZED PHASE II TRIAL OF COMBINATION THERAPY WITH MULTIPLE MYELOMA PATIENTS WITH MULTIPLE MYELOMA (MM) WHO ARE NOT CANDIDATES FOR HIGH DOSE CHEMOTHERAPY.

5. Multiple Myeloma Therapy in Newly Diagnosed Patients excluding Transplantation

POSTER DISCUSSION SESSION

Chairman: Heinz Ludwig

V. Magarotto S. G. R. Verelst S. Bringhen J. G. Berdeja E. Lee M. H. Qazilbash M. H. Qazilbash M. V. Mateos H. S. Lee

A NOVEL SMALL MOLECULE COMPOUND DISPLAYS PRECLINICAL ACTIVITY AGAINST MULTIPLE MYELOMA BY DISRUPTING THE MTOR SIGNALING PATHWAY.

BP-041 Y. Magarotto

ENABLING A NOVEL AKT/MTOR SIGNALING INHIBITOR, TP-011, TO DISRUPT THE MTHFR CYCLE IN MULTIPLE MYELOMA.

BP-042 S. G. R. Verelst

NEW TARGETED DRUGS IN MULTIPLE MYELOMA THERAPY - IN VITRO STUDIES.

BP-043 S. Bringhen

THE RELATIONSHIP OF MYELOMA BONE DISEASE SIGNALING TO THE PHARMACOLOGIES OF MULTIPLE MYELOMA - A PHARMACOLOGICAL IN VITRO STUDY.

BP-044 J. G. Berdeja

THE RELATIONSHIP OF THE PHARMACOLOGIES OF MULTIPLE MYELOMA BONE DISEASE SIGNALING AND THE EXTENT OF BONE IN VITRO STUDIES.

BP-045 E. Lee

USE OF PROTEIN-TO-CREATINE RATIO IN SPOT URINE SAMPLES FOR THE EVALUATION OF PROTEINURIA IN PATIENTS WITH MULTIPLE MYELOMA.

BP-046 M. H. Qazilbash

IMMUNE AND HORMONAL PATTERNS AND GENETIC RELATED CHANGES IN MULTIPLE MYELOMA PATIENTS.

BP-047 M. H. Qazilbash

CLINICAL SIGNIFICANCE OF GRANULOCYTE CYTOSKELETON OF NEWLY DIAGNOSED MYELOMA CELLS.

BP-048 M. V. Mateos

CLINICAL OUTCOMES OF PATIENTS WITH MELPHALAN, AND LENALIDOMIDE, PLUS HIGH DOSE DEXAMETHASONE (MC/MVR) THERAPY FOR MULTIPLE MYELOMA.

BP-049 H. S. Lee

HIGH-VERSUS ATTENUATED DOSE DEXAMETHASONE HAS LITTLE EFFECT ON THE SPEED OR DEPTH OF RESPONSE TO INDUCTION THERAPY.

BP-050 H. Giles
TREATMENT OF RENAL FAILURE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA WITH BORTEZOMIB AND DEXAMETHASONE: RESULTS OF A PHASE II TRIAL FROM PHEMA/GEM GROUP (RNVEL)

RAPID REDUCTION IN IFLC PREDICTS ACHIEVEMENT OF VGPR AFTER 4 CYCLES OF VCD TREATMENT: SHIMOUSYA MM-01 VCD STUDY

LENALIDOMIDE DOSE MODIFICATIONS AND ASSOCIATED PATIENT OUTCOMES IN NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

INTENTION TO TREAT VS AGE OF DIAGNOSIS. ANALYSIS OF BENEFICIAL EFFECT OF NEW AGENTS IN THE TREATMENT OF NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)

PATTERNS OF GROWTH FACTOR COSTS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE OR BORTEZOMIB

CYCLOPHOSPHAMIDE, BORTEZOMIB AND DEXAMETHASONE (CYBORD) FOR THE UPFRONT THERAPY OF TRANSPLANT INELIGIBLE PATIENTS WITH MULTIPLE MYELOMA

SURVIVAL OF PATIENTS WITH MULTIPLE MYELOMA IN FIRST-LINE TREATMENT: THALIDOMIDE, DEXAMETHASONE AND ZOLEDRONIC ACID. REPORT OF THE NATIONAL CANCER INSTITUTE OF MEXICO (INCAN)

INCIDENCE AND CHARACTERISTICS OF BACTERIAL INFECTIONS DURING INDUCTION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA TREATED WITH NEW DRUGS. A STUDY OF 67 PATIENTS FROM A SINGLE INSTITUTION

CYBORD DEMONSTRATED ITS SUPERIORITY TO BORTEZOMIB PLUS DEXAMETHASONE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

OUTCOMES BETWEEN FRONTLINE AND SALVAGE BORTEZOMIB-BASED REGIMENS IN ELDERLY PATIENTS WITH MULTIPLE MYELOMA

RESULTS OF THE PROTOCOL VCD FOR MULTIPLE MYELOMA IN A SINGLE CENTER IN ALGERIA

IMPROVED OUTCOME BY EARLY DOSE REDUCTION AND SCHEDULE ADJUSTMENT WITH SUBCUTANEOUS INJECTION OF BORTEZOMIB IN ELDERLY MYELOMA PATIENTS RECEIVING BORTEZOMIB-MELPHALAN-PREDNISONE REGIMEN

EFFICACY AND SAFETY OF CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE (KRd) VS LENALIDOMIDE AND DEXAMETHASONE (RD) IN PATIENTS (PTS) WITH RELAPSED MULTIPLE MYELOMA (RMM) BASED ON AGE: SECONDARY ANALYSIS FROM THE PHASE 3 STUDY ASPIRE (NCT01080391)

SUPERIOR HEALTH-RELATED QUALITY OF LIFE WITH CARFILZOMIB, LENALIDOMIDE, AND DEXAMETHASONE VS LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (MM): RESULTS FROM THE ASPIRE TRIAL

STRATUS™ (MM-010): A SINGLE-ARM, PHASE 3B STUDY EVALUATING SAFETY AND EFFICACY OF POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RMM)

SURVIVAL OUTCOMES IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RMM) IN THE MM-003 TRIAL: IMPACT OF STABLE DISEASE (SD) AS A RESPONSE TO POMALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (POM + LODEX)

SUBGROUP ANALYSIS BY PRIOR TREATMENT OF THE EFFICACY AND SAFETY OF PANOBINOSTAT PLUS BORTEZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA IN THE PANORAMA 1 STUDY

SAFETY PROFILE OF ORAL IXAZOMIB: EXPERIENCE FROM 761 PATIENTS (PTS) ACROSS 14 PHASE 1 OR PHASE 1/2 CLINICAL STUDIES

EXPOSURE-RESPONSE RELATIONSHIP OF DARATUMUMAB EFFICACY AND SAFETY IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM) AFTER PRIOR PROTEASOME INHIBITORS (PSI) AND IMMUNOMODULATORY DRUGS (IMiDS)

A PHASE I/II STUDY OF THE HUMAN CD38 ANTIBODY MOR020 (MOR30387) IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

IBRUTINIB IN COMBINATION WITH LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA: RESULTS FROM A MULTICENTER PHASE 2 TRIAL

PHASE 1 INTERIM SAFETY AND EFFICACY OF VENETOCLAX (ABT-199GDC-0199) MONOTHERAPY FOR RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA (MM)
POSTER SESSION

PO-325 M. Cavo  
ADVERSE EVENT (AE) MANAGEMENT WITH POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) IN THE STRATUS™ TRIAL: A PHASE II STUDY EVALUATING SAFETY AND EFFICACY IN PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

PO-326 P. Sonneveld  
TREATMENT (TX) WITH POMALIDOMIDE (POM) AND LOW-DOSE DEXAMETHASONE (LODEX) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI) INCLUDING THOSE ON DIAETALYSIS

PO-327 J. Matous  
A PHASE 1 STUDY OF THE PHARMACOKINETICS (PK) AND SAFETY OF POMALIDOMIDE + LOW-DOSE DEXAMETHASONE (POM+LODEX) IN PATIENTS (PTS) WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI)

PO-328 K. Weisel  
OUTCOMES OF PATIENTS (PTS) WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) AND RENAL IMPAIRMENT (RI) TREATED WITH POMALIDOMIDE (POM) + LOW-DOSE DEXAMETHASONE (LODEX) IN THE PHASE 3B STRATUS™ TRIAL (MM-010)

PO-329 A. Palumbo  
effect of age on outcomes with pomalidomide (pom) + low-dose dexamethasone (lo dex) in patients (pts) with refractory or relapsed and refractory multiple myeloma (rrmm) in the stratus™ trial (mm-010): a single-arm, phase 3b study

PO-330 M. Dimopoulos  
ELOTUZUMAB: SERUM PROTEIN ELECTROPHORESIS AND IMMUNOFIXATION INTERFERENCE WITH CLINICAL ASSESSMENT OF M-PROTEIN RESPONSE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)

PO-331 F. Patriarca  
LONG TERM FOLLOW-UP OF A DONOR VERSUS NO DONOR COMPARISON IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE AFTER PREVIOUS AUTOTRANSPLANT

PO-332 S.J. Harrison  
PHASE 1 CLINICAL TRIAL OF MARIZOMIB (MRZ, NPI-0052) IN PATIENTS WITH ADVANCED MALIGNANCIES INCLUDING MULTIPLE MYELOMA: STUDY NPI-0052-102 (NCT00629473) FINAL RESULTS

PO-333 P.L. Clemens  
PHARMACOKINETICS OF DARATUMUMAB FOLLOWING INTRAVENOUS INFUSION IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM) AFTER PRIOR PROTEASOME INHIBITOR (PI) AND IMMUNOMODULATORY DRUG (IMID) TREATMENT

PO-334 V. Montefusco  
BORTEZOMIB VERSUS LENALIDOMIDE IN MULTIPLE MYELOMA PATIENTS AT FIRST RELAPSE: FIRST INTERIM ANALYSIS OF A PHASE III STUDY

PO-335 J.F. San-Miguel  
IMPACT OF TREATMENT DURATION AND DOZING ON EFFICACY AND SAFETY IN A PHASE 3 STUDY OF PANOBINOSTAT PLUS BORTEZO-MIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED OR RE-
PO-349  A.M. Cornelison  DURABLE REMISSION AND SURVIVAL IN RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION

PO-350  E.C. Scott  AUTOPHAGY AND MTOR INHIBITION AS MECHANISMS FOR COMBATTING CHEMORESISTANCE TO STANDARD CHEMOTHERAPY: FINAL RESULTS OF A PHASE I STUDY OF INFUSIONAL CYCLOPHOSPHAMIDE (CY), PULSE DEXAMETHASONE (DEX), RAPAMYCIN (RAPA) AND HYDROXYCHLOROQUINE (HCQ)

PO-351  G. Koehne  WILMS' TUMOR 1 PROTEIN IS HIGHLY EXPRESSED ON MALIGNANT PLASMA CELLS AND PROVIDES A NOVEL TARGET FOR IMMUNOTHERAPEUTIC APPROACHES

PO-352  S. Danhof  EFFICACY AND SAFETY OF PRE-APPROVAL CARFILZOMIB-BASED THERAPY OF MULTIPLE MYELOMA IN DAILY PRACTICE – EXPERIENCE FROM A GERMAN ACADEMIC CENTER

PO-353  H. Quach  LOWER DOSE LENALIDOMIDE-DEXAMETHASONE IS LESS TOXIC AND DOES NOT COMPROMISE EFFICACY FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO ARE AGED ≥60 YEARS AND/OR WITH RENAL IMPAIRMENT AND/OR WITH THROMBOCYTOPENIA

PO-354  H. Jiang  SAR650984 (SAR) DIRECTLY INDUCES MULTIPLE MYELOMA (MM) CELL DEATH VIA LYPOSOMAL-ASSOCIATED AND APOPTOTIC PATHWAYS, WHICH IS FURTHER ENHANCED BY POMALIDOMIDE

PO-355  C. Wang  VACCINE BASED IMMUNOTHERAPY AS A STRATEGY TO BYPASS DRUG RESISTANCE IN MULTIPLE MYELOMA

PO-356  M.M. Majumder  IDENTIFICATION OF PRECISION TREATMENT STRATEGIES FOR HIGH RISK MULTIPLE MYELOMA BY EX VIVO DRUG SENSITIVITY TESTING

PO-357  S. Trudel  A PHASE 1/2 TRIAL OF THE INSULIN GROWTH FACTOR 1 RECEPTOR (IGF-1R) INHIBITOR, LINSITINIB IN COMBINATION WITH BORTEZOMIB (BTZ) AND DEXAMETHASONE (DEX) FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (MM)

PO-358  S. Strüfer  THE CONTRIBUTION OF A THIRD AUTOLOGOUS STEM CELL TRANSPLANT IN THE ERA OF NOVEL AGENTS: FAVOURABLE OVERALL SURVIVAL AND IMPROVEMENT OF EXHAUSTED BONE MARROW FUNCTION

PO-359  N. Maciocia  OUTCOME OF POMALIDOMIDE THERAPY IN RELAPSED / REFRACTORY MYELOMA: A UK MULTI-CENTRE EXPERIENCE

PO-360  A. García-Guiñon  RENAL RESPONSE IN PATIENTS (PTS) WITH RELAPSED REFRACTORY MULTIPLE MYELOMA (RRMM) AND SEVERE RENAL IMPAIRMENT (RI): INTERIM DATA FROM A LARGE OBSERVATIONAL, PROSPECTIVE STUDY

PO-361  A. Liço  LENALIDOMIDE LONG-TERM NEUROTOXICITY: NEUROPHYSIOLOGICAL FOLLOW-UP STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MYELOMA

PO-362  D.M. Sullivan  OVERCOMING PROTEASOME INHIBITOR RESISTANCE IN MULTIPLE MYELOMA USING THE XPO1: INHIBITOR SELINEXOR

PO-363  L. Rosiñol  POSTTRANSPLANT CYCLOPHOSPHAMIDE AS GVHD PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA. EXPERIENCE OF A SINGLE CENTER

PO-364  A. Gozzetti  INTRAVENOUS BORTEZOMIB (IV) INFUSION AFTER NON RESPONSE TO SUBCUTANEOUS BORTEZOMIB (SQ) ADMINISTRATION CAN INDUCE TRANSITORY RESPONSES IN MULTIPLE MYELOMA PATIENTS: IS SOME PATIENT MORE SENSITIVE TO THE IV BORTEZOMIB?

PO-365  P. Forsberg  A PHASE I STUDY OF THE ADDITION OF HIGH-DOSE LENALIDOMIDE TO MELPHalan CONDITIONING FOR AUTOLOGOUS STEM-CELL TRANSPLANT IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA

PO-366  C. Cerchione  BENDAMUSTINE-BORTEZOMIB-DEXAMETASONE (BVD) IN THE MANAGEMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA: A REGIONAL REAL-LIFE EXPERIENCE

PO-367  V.H. Jimenez Zepeda  POMALIDOMIDE-CONTAINING REGIMENS FOR THE TREATMENT OF RELAPSED AND REFRACTORY MULTIPLE MYELOMA

PO-368  J. Hou  EFFICACY AND SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSE DEXAMETHASONE (DEX; RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) ACCORDING TO DISEASE STAGE (INTERNATIONAL STAGING SYSTEM [ISS]); RESULTS FROM THE MM-021 TRIAL AND MM-024 EXTENDED ACCESS PROGRAM (EAP)

PO-369  T. Facon  TWO RANDOMIZED OPEN-LABEL STUDIES OF DARATUMUMAB (DARA) PLUS STANDARD OF CARE TREATMENT VERSUS STANDARD OF CARE ALONE IN PATIENTS WITH PREVIOUSLY UNTREATED MULTIPLE MYELOMA (MM) INELIGIBLE FOR HIGH-DOSE THERAPY: 54767414MMY3007 (ALCYONE) AND 54767414MMY3008 (MAIA)

PO-370  M.H. Qazilbash  MYELOABLATIVE TIMED SEQUENTIAL BUSULFAN IS SAFE IN PATIENTS WITH RELAPSED OR HIGH-RISK MULTIPLE MYELOMA

PO-371  C. Cerchione  PEGLYLATED LYPOSOMAL DOXORUBICINE, CYCLOPHOSPHAMIDE AND DEXAMETASONE (CED): A NEW OPPORTUNITY IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA

PO-372  H. Handa  LENALIDOMIDE EXPAND CD3+CD56+ T CELL CYTOKINE INDUCED KILLER (CIK) CELLS IN VIVO IN MULTIPLE MYELOMA PATIENTS

PO-373  L. Cesini  ORAL CYCLOPHOSPHAMIDE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS WITH BIOCHEMICAL PROGRESSION DURING LENALIDOMIDE-DEXAMETASONE TREATMENT: RESULTS OF A RETROSPECTIVE MULTICENTER ANALYSIS

PO-374  A. Leivas  MULTIPLE INFUSIONS OF AUTOLOGOUS ACTIVATED AND EXPANDED NATURAL KILLER CELLS: A NEW THERAPEUTIC OPTION FOR MIll II TIPi E MYELOMA
<table>
<thead>
<tr>
<th>ID</th>
<th>Author(s)</th>
<th>Title</th>
</tr>
</thead>
<tbody>
<tr>
<td>PO-375</td>
<td>R. Kaedbey</td>
<td>A SINGLE CENTRE RETROSPECTIVE ANALYSIS OF THE ADDITION OF CLARITHROMYCIN (BIAxin) TO LENALIDOMIDE AND DEXAMETHASONE (LEN-DEX) DURING TIME OF PROGRESSIVE DISEASE IN PATIENTS WITH MULTIPLE MYELOMA (MM)</td>
</tr>
<tr>
<td>PO-376</td>
<td>S.Y. Huang</td>
<td>A NON-INTERVENTIONAL OBSERVATIONAL REGISTRY OF PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RMM) TREATED WITH LENALIDOMIDE (LEN) AND DEXAMETHASONE (DEX) IN TAIWAN</td>
</tr>
<tr>
<td>PO-377</td>
<td>J. Lu</td>
<td>A NON-INTERVENTIONAL, OBSERVATIONAL REGISTRY OF ADULT PATIENTS WITH MULTIPLE MYELOMA TREATED WITH REVILIMID (LENALIDOMIDE) IN CHINA: INTERIM ANALYSIS</td>
</tr>
<tr>
<td>PO-378</td>
<td>I. Isola</td>
<td>PACE AS SALVAGE THERAPY FOR RELAPSED OR REFRACTORY MULTIPLE MYELOMA</td>
</tr>
<tr>
<td>PO-379</td>
<td>D.W. Sborov</td>
<td>COMBINATION CARFILZOMIB AND THE VIRAL ONCOYLYTIC AGENT REOLYSIN IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: A PILOT STUDY INVESTIGATING VIRAL PROLIFERATION</td>
</tr>
<tr>
<td>PO-380</td>
<td>A.T. Fıratlı Tuğlular</td>
<td>POST-AUTHORIZATION SAFETY OF LENALIDOMIDE + DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN TURKEY</td>
</tr>
<tr>
<td>PO-381</td>
<td>O. Miles</td>
<td>EFFICACY OF POMALIDOMIDE AFTER PROGRESSION FOLLOWING LENALIDOMIDE AND BORTEZOMIB-A MULTICENTER RETROSPECTIVE STUDY</td>
</tr>
<tr>
<td>PO-382</td>
<td>J.A. Chadwick</td>
<td>LENALIDOMIDE FOR HEAVILY PRETREATED RELAPSED/REFRACTORY MYELOMA COHORT IN NORTHWEST UNITED KINGDOM (UK) – EFFICACY &amp; TOLERABILITY: HIGH RESPONSE &amp; LOW SECOND MALIGNANCY RATES</td>
</tr>
<tr>
<td>PO-383</td>
<td>C. João</td>
<td>EFFECTIVENESS OF LENALIDOMIDE TREATMENT IN PATIENTS WITH VERY SEVERE RENAL IMPAIRMENT AND RELAPSED MULTIPLE MYELOMA</td>
</tr>
<tr>
<td>PO-384</td>
<td>J. Kwon</td>
<td>EFFICACY AND TOXICITY OF THE COMBINATION THERAPY OF THALIDOMIDE, ALKYLATING AGENT, AND CORTICOSTEROID FOR RELAPSED/REFRACTORY MYELOMA PATIENTS: A REPORT FROM THE KOREAN MULTIPLE MYELOMA WORKING PARTY (KMMWP) RETROSPECTIVE STUDY</td>
</tr>
<tr>
<td>PO-385</td>
<td>Z. Cai</td>
<td>IMPACT OF IMMUNOGLOBULIN (IG) D SUBTYPE ON THE EFFICACY AND SAFETY OF LENALIDOMIDE PLUS LOW-DOSE DEXAMETHASONE (RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM); MM-021 TRIAL</td>
</tr>
<tr>
<td>PO-386</td>
<td>J. Richter</td>
<td>POMALIDOMIDE BASED THERAPY IN PATIENTS WITH SEVERE RENAL IMPAIRMENT</td>
</tr>
<tr>
<td>PO-387</td>
<td>M. Garcia-Forbes</td>
<td>INCIDENCE OF THROMBOSIS IN MULTIPLE MYELOMA PATIENTS TREATED WITH LENALIDOMIDE-DEXAMETHASONE IN OUR CENTER. THE INFLUENCE OF RISK FACTORS</td>
</tr>
<tr>
<td>PO-388</td>
<td>Y. Aydin</td>
<td>CARFILZOMIB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA SINGLE CENTER EXPERIENCE</td>
</tr>
<tr>
<td>PO-389</td>
<td>Z. Shen</td>
<td>ECONOMIC ANALYSIS OF LENALIDOMIDE/DEXAMETHASONE (LEN-DEX) VS. BORTEZOMIB (BORT) FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA (RMM) IN CHINA</td>
</tr>
<tr>
<td>PO-390</td>
<td>S.N. Lim</td>
<td>BORTEZOMIB PRETREATMENT BEFORE ALLOGENIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR RELAPSED MULTIPLE MYELOMA</td>
</tr>
<tr>
<td>PO-391</td>
<td>A. Alegre</td>
<td>MONOCLONAL GAMMA PATHY OF RENAL SIGNIFICANCE (MGRS), RAPID HEMATOLOGICAL AND RENAL COMPLETE RESPONSE TO BORTEZOMIB</td>
</tr>
<tr>
<td>PO-392</td>
<td>L. Yu</td>
<td>SAFETY OF LENALIDOMIDE (LEN) PLUS LOW-DOSE DEXAMETHASONE (DEX, RD) IN CHINESE PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RMM) TREATED WITH PRIOR THALIDOMIDE (THAL) AND BORTEZOMIB (BORT); SUBANALYSIS OF THE MM-024 EXTENDED ACCESS PROGRAM (EAP)</td>
</tr>
<tr>
<td>PO-393</td>
<td>K.S. Jung</td>
<td>THE EFFICACY AND SAFETY OF LENALIDOMIDE IN MULTIPLE MYELOMA WITH SEVERE RENAL IMPAIRMENT</td>
</tr>
<tr>
<td>PO-394</td>
<td>M.I. Pereira</td>
<td>A NATIONAL EXPERIENCE OF THE EFFICACY AND SAFETY OF LONG-TERM TREATMENT WITH LENALIDOMIDE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA</td>
</tr>
<tr>
<td>PO-395</td>
<td>R. Haznedar</td>
<td>IS URINE IMMUNOFACTOR ELECTROPHORESIS NECESSARY FOR MONITORING MYELOMA PATIENTS WHO HAS UNDERGONE HEMATOPOIETIC STEM CELL TRANSPLANTATION</td>
</tr>
<tr>
<td>PO-396</td>
<td>C. Montes Gaisan</td>
<td>POMALIDOMIDE IN REFRACTORY MULTIPLE MYELOMA (MMRR): A SINGLE CENTER EXPERIENCE</td>
</tr>
<tr>
<td>PO-397</td>
<td>H.J. Kim</td>
<td>METRONOMIC CHEMOTHERAPY OF THALIDOMIDE, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS</td>
</tr>
<tr>
<td>PO-398</td>
<td>G. Mele</td>
<td>SYNCHRONOUS LOCALIZATIONS OF MULTIPLE MYELOMA IN 3 DIFFERENT SITES (ETHMOIDAL SINUSES, TESTICLES AND SKIN) DURING THE COURSE OF MULTIPLE MYELOMA (MM) THERAPY</td>
</tr>
<tr>
<td>PO-399</td>
<td>S. Ongoren</td>
<td>IGD MULTIPLE MYELOMA, DESCRIPTIVE REPORT OF EIGHT CASES, SINGLE CENTRE EXPERIENCE</td>
</tr>
<tr>
<td>PO-400</td>
<td>M. Steinbach</td>
<td>CASE REPORT: POMALIDOMIDE AS CONSOLIDATION THERAPY AFTER SALVAGE AUTOLOGOUS STEM CELL TRANSPLANT</td>
</tr>
</tbody>
</table>

**MYELOMA WORKSHOP**

Auditorium Parco della Musica
7. Nurse Session

POSTER SESSION

PO-401  A. Bernardini  MANAGEMENT OF TOXICITIES ASSOCIATED WITH CARFILZOMIB: AN UPDATE OF THE ITALIAN EXPERIENCE

PO-402  C. Woodrow  DEVELOPING SAFE HEMATOLOGICAL MONITORING GUIDELINES FOR PATIENTS WITH MYELOMA ON BORTEZOMIB BASED REGIMENS

PO-403  C. Marrin  HOW A PATIENT SATISFACTION SURVEY CAN ENHANCE A MYELOMA OUT PATIENT CLINIC

PO-404  H. King  ARE THE MYELOMA POPULATION COMPUTER LITERATE? – SQUASHING THE SNAIL MAIL

PO-405  J. Helwlett  DEVELOPING A NURSE LED, HOLISTIC NEEDS ASSESSMENT CLINIC FOR MYELOMA PATIENTS

ABSTRACT REVIEWERS

Nizar J. Bahlis  Calgary, Canada
Sara Bringhen  Torino, Italy
Raymond L. Comenzo  Boston, USA
Meletios A. Dimopoulos  Athens, Greece
Angela Dispenzieri  Rochester, USA
Beth Fainan  Cleveland, USA
Francesca Gay  Torino, Italy
Irene M. Ghobrial  Boston, USA
Andrzej Jakubowiak  Chicago, USA
Tracy King  Sydney, Australia
Shaji K. Kumar  Rochester, USA
Sagar Lonial  Atlanta, USA
Valeria Magarotto  Torino, Italy
Maria-Victoria Mateos  Salamanca, Spain
Giampalolo Merlini  Pavia, Italy
Fortunato Morabito  Cosenza, Italy
Gareth J. Morgan  Little Rock, USA
Pellegrino Musto  Rionero in Vulture (PZ), Italy
Massimo Offidani  Ancona, Italy
Stefania Oliva  Torino, Italy
Torben Plesner  Vejle, Denmark
Noopur Raje  Boston, USA
S. Vincent Rajkumar  Rochester, USA
Andrew Spencer  Melbourne, Australia
A. Keith Stewart  Scottsdale, USA
Elena Zamagni  Bologna, Italy
Sonja Zweegman  Amsterdam, The Netherlands